Harald Arnesen

  • Professor em.; MD, PhD, FESC

Founder of Center for Clinical Heart Research

 

Publications 2024

Aune SK, Helseth R, Kalstad AA, Laake K, Åkra S, Arnesen H, Solheim S, Seljeflot I (2024)
Links Between Adipose Tissue Gene Expression of Gut Leakage Markers, Circulating Levels, Anthropometrics, and Diet in Patients with Coronary Artery Disease
Diabetes Metab Syndr Obes, 17, 2177-2190
DOI 10.2147/DMSO.S438818, PubMed 38827167

Publications 2023

Gragnano F, Cao D, Pirondini L, Franzone A, Kim HS, von Scheidt M, Pettersen AR, Zhao Q, Woodward M, Chiarito M, McFadden EP, Park KW, Kastrati A, Seljeflot I, Zhu Y, Windecker S, Kang J, Schunkert H, Arnesen H, Bhatt DL, Steg PG, Calabrò P, Pocock S, Mehran R, Valgimigli M et al. (2023)
P2Y12 Inhibitor or Aspirin Monotherapy for Secondary Prevention of Coronary Events
J Am Coll Cardiol, 82 (2), 89-105
DOI 10.1016/j.jacc.2023.04.051, PubMed 37407118

Myhre PL, Berge T, Kalstad AA, Tveit SH, Laake K, Schmidt EB, Solheim S, Arnesen H, Seljeflot I, Tveit A (2023)
Omega-3 fatty acid supplements and risk of atrial fibrillation and 'micro-atrial fibrillation': A secondary analysis from the OMEMI trial
Clin Nutr, 42 (9), 1657-1660
DOI 10.1016/j.clnu.2023.07.002, PubMed 37515843

Papotti B, Opstad TB, Åkra S, Tønnessen T, Braathen B, Hansen CH, Arnesen H, Solheim S, Seljeflot I, Ronda N (2023)
Macrophage polarization markers in subcutaneous, pericardial, and epicardial adipose tissue are altered in patients with coronary heart disease
Front Cardiovasc Med, 10, 1055069
DOI 10.3389/fcvm.2023.1055069, PubMed 36937936

Warlo EMK, Kalstad AA, Myhre PL, Solheim S, Arnesen H, Tveit A, Holme PA, Seljeflot I, Bratseth V (2023)
von Willebrand factor, ADAMTS-13, and thrombospondin 1 in relation to clinical outcomes in elderly patients with a recent myocardial infarction
Res Pract Thromb Haemost, 7 (4), 100164
DOI 10.1016/j.rpth.2023.100164, PubMed 37255854

Publications 2022

Berge T, Myhre PL, Kalstad AA, Laake K, Tveit SH, Onarheim S, Solheim S, Seljeflot I, Arnesen H, Tveit A (2022)
Screen-Detected Atrial Fibrillation and "Micro-Atrial Fibrillation" and Risk of Cardiovascular Events after Myocardial Infarction in Elderly Patients
Cardiology, 148 (1), 72-77
DOI 10.1159/000528726, PubMed 36538900

Bratseth V, Nordeng J, Helseth R, Solheim S, Åkra S, Arnesen H, Chiva-Blanch G, Seljeflot I (2022)
Circulating Microvesicles in Association with the NLRP3 Inflammasome in Coronary Thrombi from STEMI Patients
Biomedicines, 10 (9)
DOI 10.3390/biomedicines10092196, PubMed 36140297

Cwikiel J, Fagerland MW, Wachtell K, Arnesen H, Seljeflot I, Flaa A (2022)
Exercise-induced change in circulating NT-proBNP could not distinguish between patients with and without coronary artery disease: the CADENCE study
Scand Cardiovasc J, 56 (1), 107-113
DOI 10.1080/14017431.2022.2075562, PubMed 35593516

Hansen CH, Cwikiel J, Bratseth V, Arnesen H, Flaa A, Seljeflot I (2022)
Effect of Revascularization on Exercise-Induced Changes in Cardiac and Prothrombotic Biomarkers in Patients with Coronary Artery Disease
Clin Appl Thromb Hemost, 28, 10760296221094029
DOI 10.1177/10760296221094029, PubMed 35437054

Kluge KE, Langseth MS, Andersen GØ, Halvorsen S, Opstad TB, Arnesen H, Tønnessen T, Seljeflot I, Helseth R (2022)
Complement activation in association with clinical outcomes in ST-elevation myocardial infarction
Am Heart J Plus, 24, 100228
DOI 10.1016/j.ahjo.2022.100228, PubMed 38560636

Kluge KE, Seljeflot I, Arnesen H, Jensen T, Halvorsen S, Helseth R (2022)
Coagulation factors XI and XII as possible targets for anticoagulant therapy
Thromb Res, 214, 53-62
DOI 10.1016/j.thromres.2022.04.013, PubMed 35490644

Myhre PL, Kalstad AA, Tveit SH, Laake K, Schmidt EB, Smith P, Nilsen DWT, Tveit A, Solheim S, Arnesen H, Seljeflot I (2022)
Changes in eicosapentaenoic acid and docosahexaenoic acid and risk of cardiovascular events and atrial fibrillation: A secondary analysis of the OMEMI trial
J Intern Med, 291 (5), 637-647
DOI 10.1111/joim.13442, PubMed 34982486

Nordeng J, Schandiz H, Solheim S, Åkra S, Hoffman P, Roald B, Bendz B, Arnesen H, Helseth R, Seljeflot I (2022)
TIMP-1 expression in coronary thrombi associate with myocardial injury in ST-elevation myocardial infarction patients
Coron Artery Dis, 33 (6), 446-455
DOI 10.1097/MCA.0000000000001128, PubMed 35102064

Nordeng J, Solheim S, Åkra S, Schandiz H, Hoffmann P, Roald B, Bendz B, Arnesen H, Helseth R, Seljeflot I (2022)
Gene expression of fibrinolytic markers in coronary thrombi
Thromb J, 20 (1), 23
DOI 10.1186/s12959-022-00383-1, PubMed 35488283

Opstad TB, Solheim S, Pettersen AR, Kalstad AA, Arnesen H, Seljeflot I (2022)
TERT and TET2 Genetic Variants Affect Leukocyte Telomere Length and Clinical Outcome in Coronary Artery Disease Patients-A Possible Link to Clonal Hematopoiesis
Biomedicines, 10 (8)
DOI 10.3390/biomedicines10082027, PubMed 36009574

Warlo EMK, Bratseth V, Pettersen AR, Holme PA, Arnesen H, Seljeflot I, Opstad TB (2022)
Genetic Variation in ADAMTS13 is Related to VWF Levels, Atrial Fibrillation and Cerebral Ischemic Events
Clin Appl Thromb Hemost, 28, 10760296221141893
DOI 10.1177/10760296221141893, PubMed 36474435

Åkra S, Seljeflot I, Braathen B, Bratseth V, Hansen CH, Arnesen H, Tønnessen T, Solheim S (2022)
The NLRP3 inflammasome activation in subcutaneous, epicardial and pericardial adipose tissue in patients with coronary heart disease undergoing coronary by-pass surgery
Atheroscler Plus, 48, 47-54
DOI 10.1016/j.athplu.2022.03.005, PubMed 36644557

Publications 2021

Aune SK, Byrkjeland R, Solheim S, Arnesen H, Trøseid M, Awoyemi A, Seljeflot I, Helseth R (2021)
Gut related inflammation and cardiorespiratory fitness in patients with CAD and type 2 diabetes: a sub-study of a randomized controlled trial on exercise training
Diabetol Metab Syndr, 13 (1), 36
DOI 10.1186/s13098-021-00655-2, PubMed 33794977

Aune SK, Cwikiel J, Flaa A, Arnesen H, Solheim S, Awoyemi A, Trøseid M, Seljeflot I, Helseth R (2021)
Gut Leakage Markers in Response to Strenuous Exercise in Patients with Suspected Coronary Artery Disease
Cells, 10 (9)
DOI 10.3390/cells10092193, PubMed 34571843

Chiva-Blanch G, Bratseth V, Laake K, Arnesen H, Solheim S, Schmidt EB, Badimon L, Seljeflot I (2021)
One year of omega 3 polyunsaturated fatty acid supplementation does not reduce circulating prothrombotic microvesicles in elderly subjects after suffering a myocardial infarction
Clin Nutr, 40 (12), 5674-5677
DOI 10.1016/j.clnu.2021.10.007, PubMed 34742136

Kalstad AA, Myhre PL, Laake K, Opstad TB, Tveit A, Solheim S, Arnesen H, Seljeflot I (2021)
Biomarkers of ageing and cardiac remodeling are associated with atrial fibrillation
Scand Cardiovasc J, 55 (4), 213-219
DOI 10.1080/14017431.2021.1889653, PubMed 33650449

Myhre P, Seljeflot I, Arnesen H (2021)
[Myhre, Seljeflot and Arnesen respond]
Tidsskr Nor Laegeforen, 141 (10)
DOI 10.4045/tidsskr.21.0470, PubMed 34182730

Myhre PL, Seljeflot I, Arnesen H (2021)
Omega-3 supplements do not prevent cardiovascular disease
Tidsskr Nor Laegeforen, 141 (6)
DOI 10.4045/tidsskr.21.0033, PubMed 33876607

Myhre PL, Seljeflot I, Arnesen H (2021)
Omega-3 supplements do not prevent cardiovascular disease
Tidsskr. Nor. Laegeforen., 141 (6), 536-538

Nilsen DWT, Myhre PL, Kalstad A, Schmidt EB, Arnesen H, Seljeflot I (2021)
Serum Levels of Dihomo-Gamma (γ)-Linolenic Acid (DGLA) Are Inversely Associated with Linoleic Acid and Total Death in Elderly Patients with a Recent Myocardial Infarction
Nutrients, 13 (10)
DOI 10.3390/nu13103475, PubMed 34684479

Nordeng J, Schandiz H, Solheim S, Åkra S, Hoffman P, Roald B, Bendz B, Arnesen H, Helseth R, Seljeflot I (2021)
The Inflammasome Signaling Pathway Is Actively Regulated and Related to Myocardial Damage in Coronary Thrombi from Patients with STEMI
Mediators Inflamm, 2021, 5525917
DOI 10.1155/2021/5525917, PubMed 34135690

Zaidi H, Byrkjeland R, Njerve IU, Åkra S, Solheim S, Arnesen H, Seljeflot I, Opstad TB (2021)
Adiponectin in relation to exercise and physical performance in patients with type 2 diabetes and coronary artery disease
Adipocyte, 10 (1), 612-620
DOI 10.1080/21623945.2021.1996699, PubMed 34779349

Publications 2020

Arnesen H, Myhre PL, Seljeflot I (2020)
Very Long Chain Marine n-3 Polyunsaturated Fatty Acids in Atherothrombotic Heart Disease. A Brief Review, with a Focus on Metabolic Effects
Nutrients, 12 (10)
DOI 10.3390/nu12103014, PubMed 33008057

Bratseth V, Margeirsdottir HD, Chiva-Blanch G, Heier M, Solheim S, Arnesen H, Dahl-Jørgensen K, Seljeflot I (2020)
Annexin V+ Microvesicles in Children and Adolescents with Type 1 Diabetes: A Prospective Cohort Study
J Diabetes Res, 2020, 7216863
DOI 10.1155/2020/7216863, PubMed 32309448

Bratseth V, Margeirsdottir HD, Heier M, Solheim S, Arnesen H, Dahl-Jørgensen K, Seljeflot I (2020)
Procoagulant activity in children and adolescents on intensive insulin therapy
Pediatr Diabetes, 21 (3), 496-504
DOI 10.1111/pedi.12978, PubMed 31943582

Hilde JM, Hisdal J, Skjørten I, Hansteen V, Melsom MN, Grøtta OJ, Småstuen MC, Seljeflot I, Arnesen H, Humerfelt S, Steine K (2020)
Left ventricular dysfunction in COPD without pulmonary hypertension
PLoS One, 15 (7), e0235075
DOI 10.1371/journal.pone.0235075, PubMed 32673327

Kalstad AA, Myhre PL, Laake K, Tveit SH, Schmidt EB, Smith P, Nilsen DWT, Tveit A, Fagerland MW, Solheim S, Seljeflot I, Arnesen H, OMEMI Investigators (2020)
Effects of n-3 Fatty Acid Supplements in Elderly Patients After Myocardial Infarction: A Randomized, Controlled Trial
Circulation, 143 (6), 528-539
DOI 10.1161/CIRCULATIONAHA.120.052209, PubMed 33191772

Kluge KE, Langseth MS, Bratseth V, Pettersen AÅ, Arnesen H, Tønnessen T, Seljeflot I, Helseth R (2020)
Circulating levels of the terminal complement complex are associated with hypercoagulability in patients with stable coronary artery disease
Thromb Res, 196, 106-108
DOI 10.1016/j.thromres.2020.08.023, PubMed 32853976

Kluge KE, Langseth MS, Opstad TB, Pettersen AÅ, Arnesen H, Tønnessen T, Seljeflot I, Helseth R (2020)
Complement Activation in Association with Markers of Neutrophil Extracellular Traps and Acute Myocardial Infarction in Stable Coronary Artery Disease
Mediators Inflamm, 2020, 5080743
DOI 10.1155/2020/5080743, PubMed 32308555

Langseth MS, Andersen GØ, Husebye T, Arnesen H, Zucknick M, Solheim S, Eritsland J, Seljeflot I, Opstad TB, Helseth R (2020)
Neutrophil extracellular trap components and myocardial recovery in post-ischemic acute heart failure
PLoS One, 15 (10), e0241333
DOI 10.1371/journal.pone.0241333, PubMed 33119664

Langseth MS, Helseth R, Ritschel V, Hansen CH, Andersen GØ, Eritsland J, Halvorsen S, Fagerland MW, Solheim S, Arnesen H, Seljeflot I, Opstad TB (2020)
Double-Stranded DNA and NETs Components in Relation to Clinical Outcome After ST-Elevation Myocardial Infarction
Sci Rep, 10 (1), 5007
DOI 10.1038/s41598-020-61971-7, PubMed 32193509

Monin L, Ushakov DS, Arnesen H, Bah N, Jandke A, Muñoz-Ruiz M, Carvalho J, Joseph S, Almeida BC, Green MJ, Nye E, Hatano S, Yoshikai Y, Curtis M, Carlsen H, Steinhoff U, Boysen P, Hayday A (2020)
γδ T cells compose a developmentally regulated intrauterine population and protect against vaginal candidiasis
Mucosal Immunol, 13 (6), 969-981
DOI 10.1038/s41385-020-0305-7, PubMed 32472066

Opstad TB, Berg TJ, Holte KB, Arnesen H, Solheim S, Seljeflot I (2020)
Reduced leukocyte telomere lengths and sirtuin 1 gene expression in long-term survivors of type 1 diabetes: A Dialong substudy
J Diabetes Investig, 12 (7), 1183-1192
DOI 10.1111/jdi.13470, PubMed 33249778

Opstad TB, Kalstad AA, Holte KB, Berg TJ, Solheim S, Arnesen H, Seljeflot I (2020)
Shorter Leukocyte Telomere Lengths in Healthy Relatives of Patients with Coronary Heart Disease
Rejuvenation Res, 23 (4), 324-332
DOI 10.1089/rej.2019.2258, PubMed 31805818

Publications 2019

Awoyemi A, Trøseid M, Arnesen H, Solheim S, Seljeflot I (2019)
Effects of dietary intervention and n-3 PUFA supplementation on markers of gut-related inflammation and their association with cardiovascular events in a high-risk population
Atherosclerosis, 286, 53-59
DOI 10.1016/j.atherosclerosis.2019.05.004, PubMed 31100620

Bratseth V, Chiva-Blanch G, Byrkjeland R, Solheim S, Arnesen H, Seljeflot I (2019)
Elevated levels of circulating microvesicles in coronary artery disease patients with type 2 diabetes and albuminuria: Effects of exercise training
Diab Vasc Dis Res, 16 (5), 431-439
DOI 10.1177/1479164119843094, PubMed 31023084

Chiva-Blanch G, Laake K, Myhre P, Bratseth V, Arnesen H, Solheim S, Badimon L, Seljeflot I (2019)
High Adherence to the Nordic Diet Is Associated with Lower Levels of Total and Platelet-Derived Circulating Microvesicles in a Norwegian Population
Nutrients, 11 (5)
DOI 10.3390/nu11051114, PubMed 31109111

Cwikiel J, Seljeflot I, Fagerland MW, Wachtell K, Arnesen H, Berge E, Flaa A (2019)
High-sensitive cardiac Troponin T and exercise stress test for evaluation of angiographically significant coronary disease
Int J Cardiol, 287, 1-6
DOI 10.1016/j.ijcard.2019.04.019, PubMed 31006595

Helseth R, Knudsen EC, Eritsland J, Opstad TB, Arnesen H, Andersen GØ, Seljeflot I (2019)
Glucose associated NETosis in patients with ST-elevation myocardial infarction: an observational study
BMC Cardiovasc Disord, 19 (1), 221
DOI 10.1186/s12872-019-1205-1, PubMed 31615411

Helseth R, Shetelig C, Andersen GØ, Langseth MS, Limalanathan S, Opstad TB, Arnesen H, Hoffmann P, Eritsland J, Seljeflot I (2019)
Neutrophil Extracellular Trap Components Associate with Infarct Size, Ventricular Function, and Clinical Outcome in STEMI
Mediators Inflamm, 2019, 7816491
DOI 10.1155/2019/7816491, PubMed 31772506

Kalstad AA, Tveit S, Myhre PL, Laake K, Opstad TB, Tveit A, Schmidt EB, Solheim S, Arnesen H, Seljeflot I (2019)
Leukocyte telomere length and serum polyunsaturated fatty acids, dietary habits, cardiovascular risk factors and features of myocardial infarction in elderly patients
BMC Geriatr, 19 (1), 376
DOI 10.1186/s12877-019-1383-9, PubMed 31881852

Knudsen EC, Seljeflot I, Aksnes TA, Eritsland J, Arnesen H, Andersen GØ (2019)
IgM antibodies against phosphorylcholine measured early after acute ST-elevation myocardial infarction in relation to atherosclerotic disease burden and long-term clinical outcome
PLoS One, 14 (4), e0215640
DOI 10.1371/journal.pone.0215640, PubMed 31002684

Opstad TB, Kalstad AA, Pettersen AÅ, Arnesen H, Seljeflot I (2019)
Novel biomolecules of ageing, sex differences and potential underlying mechanisms of telomere shortening in coronary artery disease
Exp Gerontol, 119, 53-60
DOI 10.1016/j.exger.2019.01.020, PubMed 30684534

Warlo EMK, Arnesen H, Seljeflot I (2019)
A brief review on resistance to P2Y12 receptor antagonism in coronary artery disease
Thromb J, 17, 11
DOI 10.1186/s12959-019-0197-5, PubMed 31198410

Zaidi H, Byrkjeland R, Njerve IU, Åkra S, Solheim S, Arnesen H, Seljeflot I, Opstad TB (2019)
Effects of exercise training on inflammasome-related mediators and their associations to glucometabolic variables in patients with combined coronary artery disease and type 2 diabetes mellitus: Sub-study of a randomized control trial
Diab Vasc Dis Res, 16 (4), 360-368
DOI 10.1177/1479164119836922, PubMed 30939905

Zaidi H, Byrkjeland R, Njerve IU, Åkra S, Solheim S, Arnesen H, Seljeflot I, Opstad TB (2019)
Effects of exercise training on markers of adipose tissue remodeling in patients with coronary artery disease and type 2 diabetes mellitus: sub study of the randomized controlled EXCADI trial
Diabetol Metab Syndr, 11, 109
DOI 10.1186/s13098-019-0508-9, PubMed 31890043

Publications 2018

Awoyemi A, Trøseid M, Arnesen H, Solheim S, Seljeflot I (2018)
Markers of metabolic endotoxemia as related to metabolic syndrome in an elderly male population at high cardiovascular risk: a cross-sectional study
Diabetol Metab Syndr, 10, 59
DOI 10.1186/s13098-018-0360-3, PubMed 30038669

Cwikiel J, Seljeflot I, Berge E, Njerve IU, Ulsaker H, Arnesen H, Flaa A (2018)
Effect of strenuous exercise on mediators of inflammation in patients with coronary artery disease
Cytokine, 105, 17-22
DOI 10.1016/j.cyto.2018.02.006, PubMed 29433015

Hansen CH, Ritschel V, Andersen GØ, Halvorsen S, Eritsland J, Arnesen H, Seljeflot I (2018)
Markers of Thrombin Generation Are Associated With Long-Term Clinical Outcome in Patients With ST-Segment Elevation Myocardial Infarction
Clin Appl Thromb Hemost, 24 (7), 1088-1094
DOI 10.1177/1076029618764847, PubMed 29695176

Horjen AW, Ulimoen SR, Norseth J, Svendsen JH, Smith P, Arnesen H, Seljeflot I, Tveit A (2018)
High-sensitivity troponin I in persistent atrial fibrillation - relation to NT-proBNP and markers of inflammation and haemostasis
Scand J Clin Lab Invest, 78 (5), 386-392
DOI 10.1080/00365513.2018.1481224, PubMed 29933716

Langseth MS, Opstad TB, Bratseth V, Solheim S, Arnesen H, Pettersen AÅ, Seljeflot I, Helseth R (2018)
Markers of neutrophil extracellular traps are associated with adverse clinical outcome in stable coronary artery disease
Eur J Prev Cardiol, 25 (7), 762-769
DOI 10.1177/2047487318760618, PubMed 29473463

Publications 2017

Abdelnoor M, Andersen JG, Arnesen H, Johansen O (2017)
Early discharge compared with ordinary discharge after percutaneous coronary intervention - a systematic review and meta-analysis of safety and cost
Vasc Health Risk Manag, 13, 101-109
DOI 10.2147/VHRM.S122951, PubMed 28356750

Bratseth V, Byrkjeland R, Njerve IU, Solheim S, Arnesen H, Seljeflot I (2017)
Procoagulant activity in patients with combined type 2 diabetes and coronary artery disease: No effects of long-term exercise training
Diab Vasc Dis Res, 14 (2), 144-151
DOI 10.1177/1479164116679080, PubMed 28111966

Byrkjeland R, Njerve IU, Arnesen H, Seljeflot I, Solheim S (2017)
Reduced endothelial activation after exercise is associated with improved HbA1c in patients with type 2 diabetes and coronary artery disease
Diab Vasc Dis Res, 14 (2), 94-103
DOI 10.1177/1479164116679077, PubMed 28111980

Chiva-Blanch G, Laake K, Myhre P, Bratseth V, Arnesen H, Solheim S, Badimon L, Seljeflot I (2017)
Platelet-, monocyte-derived and tissue factor-carrying circulating microparticles are related to acute myocardial infarction severity
PLoS One, 12 (2), e0172558
DOI 10.1371/journal.pone.0172558, PubMed 28207887

Cwikiel J, Seljeflot I, Berge E, Arnesen H, Wachtell K, Ulsaker H, Flaa A (2017)
Pro-coagulant activity during exercise testing in patients with coronary artery disease
Thromb J, 15, 3
DOI 10.1186/s12959-016-0127-8, PubMed 28115916

Gharagozlian S, Hansen R, Haugen M, Johansen O, Seierstad SL, Seljeflot I, Arnesen H (2017)
Changes in dietary pattern when including 700 g of salmon per week to patients with atherosclerotic heart disease
Clin. Nutr. ESPEN, 19, 38-44
DOI 10.1016/j.clnesp.2017.02.004

Horjen AW, Seljeflot I, Berge T, Smith P, Arnesen H, Tveit A (2017)
Effect of sinus rhythm restoration on markers of thrombin generation in atrial fibrillation
Thromb J, 15, 30
DOI 10.1186/s12959-017-0153-1, PubMed 29299030

Laake K, Seljeflot I, Schmidt EB, Myhre P, Tveit A, Norseth J, Arnesen H, Solheim S (2017)
Galectin-3, a marker of cardiac remodeling, is inversely related to serum levels of marine omega-3 fatty acids. A cross-sectional study
JRSM Cardiovasc Dis, 6, 2048004017729984
DOI 10.1177/2048004017729984, PubMed 28932392

Njerve IU, Åkra S, Weiss TW, Solheim S, Øvstebø R, Aass HCD, Byrkjeland R, Arnesen H, Seljeflot I (2017)
A Double-Blinded Randomized Study Investigating a Possible Anti-Inflammatory Effect of Saxagliptin versus Placebo as Add-On Therapy in Patients with Both Type 2 Diabetes And Stable Coronary Artery Disease
Mediators Inflamm, 2017, 5380638
DOI 10.1155/2017/5380638, PubMed 28596642

Opstad TB, Seljeflot I, Bøhmer E, Arnesen H, Halvorsen S (2017)
MMP-9 and Its Regulators TIMP-1 and EMMPRIN in Patients with Acute ST-Elevation Myocardial Infarction: A NORDISTEMI Substudy
Cardiology, 139 (1), 17-24
DOI 10.1159/000481684, PubMed 29141241

Ritschel V, Shetelig C, Seljeflot I, Limalanathan S, Hoffmann P, Halvorsen S, Arnesen H, Eritsland J, Andersen GØ (2017)
Evaluation of circulating levels of CCN2/connective tissue growth factor in patients with ST-elevation myocardial infarction
Sci Rep, 7 (1), 11945
DOI 10.1038/s41598-017-12372-w, PubMed 28931920

Warlo EMK, Pettersen AR, Arnesen H, Seljeflot I (2017)
vWF/ADAMTS13 is associated with on-aspirin residual platelet reactivity and clinical outcome in patients with stable coronary artery disease
Thromb J, 15, 28
DOI 10.1186/s12959-017-0151-3, PubMed 29200971

Publications 2016

Byrkjeland R, Stensæth KH, Anderssen S, Njerve IU, Arnesen H, Seljeflot I, Solheim S (2016)
Effects of exercise training on carotid intima-media thickness in patients with type 2 diabetes and coronary artery disease. Influence of carotid plaques
Cardiovasc Diabetol, 15, 13
DOI 10.1186/s12933-016-0336-2, PubMed 26801098

Chiva-Blanch G, Bratseth V, Ritschel V, Andersen GØ, Halvorsen S, Eritsland J, Arnesen H, Badimon L, Seljeflot I (2016)
Monocyte-derived circulating microparticles (CD14+, CD14+/CD11b+ and CD14+/CD142+) are related to long-term prognosis for cardiovascular mortality in STEMI patients
Int J Cardiol, 227, 876-881
DOI 10.1016/j.ijcard.2016.11.302, PubMed 27915085

De Caterina R, Husted S, Wallentin L, Andreotti F, Arnesen H, Bachmann F, Baigent C, Collet JP, Halvorsen S, Huber K, Jespersen J, Kristensen SD, Lip GY, Morais J, Rasmussen LH, Ricci F, Sibbing D, Siegbahn A, Storey RF, Ten Berg J, Verheugt FW, Weitz JI (2016)
Oral anticoagulants in coronary heart disease (Section IV). Position paper of the ESC Working Group on Thrombosis - Task Force on Anticoagulants in Heart Disease
Thromb Haemost, 115 (4), 685-711
DOI 10.1160/TH15-09-0703, PubMed 26952877

Helseth R, Solheim S, Arnesen H, Seljeflot I, Opstad TB (2016)
The Time Course of Markers of Neutrophil Extracellular Traps in Patients Undergoing Revascularisation for Acute Myocardial Infarction or Stable Angina Pectoris
Mediators Inflamm, 2016, 2182358
DOI 10.1155/2016/2182358, PubMed 28074081

Horjen AW, Ulimoen SR, Enger S, Norseth J, Seljeflot I, Arnesen H, Tveit A (2016)
Troponin I levels in permanent atrial fibrillation-impact of rate control and exercise testing
BMC Cardiovasc Disord, 16, 79
DOI 10.1186/s12872-016-0255-x, PubMed 27142292

Laake K, Seljeflot I, Schmidt EB, Myhre P, Tveit A, Arnesen H, Solheim S (2016)
Serum Fatty Acids, Traditional Risk Factors, and Comorbidity as Related to Myocardial Injury in an Elderly Population with Acute Myocardial Infarction
J Lipids, 2016, 4945720
DOI 10.1155/2016/4945720, PubMed 26989512

Myhre PL, Laake K, Seljeflot I, Solheim S, Arnesen H (2016)
[Clinical research on elderly]
Tidsskr Nor Laegeforen, 136 (3), 208
DOI 10.4045/tidsskr.15.1300, PubMed 26860377

Njerve IU, Byrkjeland R, Arnesen H, Åkra S, Solheim S, Seljeflot I (2016)
Effects of long-term exercise training on adipose tissue expression of fractalkine and MCP-1 in patients with type 2 diabetes and stable coronary artery disease: a substudy of a randomized controlled trial
Diabetes Metab Syndr Obes, 9, 55-62
DOI 10.2147/DMSO.S96299, PubMed 27042130

Opstad TB, Arnesen H, Pettersen AÅ, Seljeflot I (2016)
Combined Elevated Levels of the Proinflammatory Cytokines IL-18 and IL-12 Are Associated with Clinical Events in Patients with Coronary Artery Disease: An Observational Study
Metab Syndr Relat Disord, 14 (5), 242-8
DOI 10.1089/met.2015.0130, PubMed 27058587

Opstad TB, Brusletto BS, Arnesen H, Pettersen AÅ, Seljeflot I (2016)
Cigarette smoking represses expression of cytokine IL-12 and its regulator miR-21-An observational study in patients with coronary artery disease
Immunobiology, 222 (2), 169-175
DOI 10.1016/j.imbio.2016.10.007, PubMed 27765464

Ritschel VN, Seljeflot I, Arnesen H, Halvorsen S, Eritsland J, Fagerland MW, Andersen GØ (2016)
Circulating Levels of IL-6 Receptor and gp130 and Long-Term Clinical Outcomes in ST-Elevation Myocardial Infarction
J Am Heart Assoc, 5 (6)
DOI 10.1161/JAHA.115.003014, PubMed 27412895

Publications 2015

Andric T, Weiss TW, Huber K, Arnesen H, Seljeflot I (2015)
Effects of diet and/or n-3 fatty acid supplementation on components of the interleukin-6 trans-signalling system in elderly men
Scand J Clin Lab Invest, 75 (8), 646-51
DOI 10.3109/00365513.2015.1063002, PubMed 26179891

Bethke A, Halvorsen S, Bøhmer E, Abdelnoor M, Arnesen H, Hoffmann P (2015)
Myocardial perfusion grade predicts final infarct size and left ventricular function in patients with ST-elevation myocardial infarction treated with a pharmaco-invasive strategy (thrombolysis and early angioplasty)
EuroIntervention, 11 (5), 518-24
DOI 10.4244/EIJY15M04_02, PubMed 25868877

Byrkjeland R, Njerve IU, Anderssen S, Arnesen H, Seljeflot I, Solheim S (2015)
Effects of exercise training on HbA1c and VO2peak in patients with type 2 diabetes and coronary artery disease: A randomised clinical trial
Diab Vasc Dis Res, 12 (5), 325-33
DOI 10.1177/1479164115590552, PubMed 26092822

Hansen CH, Ritschel V, Halvorsen S, Andersen GØ, Bjørnerheim R, Eritsland J, Arnesen H, Seljeflot I (2015)
Markers of thrombin generation are associated with myocardial necrosis and left ventricular impairment in patients with ST-elevation myocardial infarction
Thromb J, 13, 31
DOI 10.1186/s12959-015-0061-1, PubMed 26396552

Helseth R, Opstad T, Solheim S, Lunde K, Arnesen H, Seljeflot I (2015)
The Effect of Intracoronary Stem Cell Injection on Markers of Leukocyte Activation in Acute Myocardial Infarction
Cardiol Res, 6 (1), 209-215
DOI 10.14740/cr375w, PubMed 28197227

Helseth R, Weiss TW, Opstad TB, Siegbahn A, Solheim S, Freynhofer MK, Huber K, Arnesen H, Seljeflot S (2015)
Associations between circulating proteins and corresponding genes expressed in coronary thrombi in patients with acute myocardial infarction
Thromb Res, 136 (6), 1240-4
DOI 10.1016/j.thromres.2015.10.005, PubMed 26475405

Horjen AW, Ulimoen SR, Seljeflot I, Smith P, Arnesen H, Norseth J, Tveit A (2015)
High-Sensitivity Troponin I and Rhythm Outcome after Electrical Cardioversion for Persistent Atrial Fibrillation
Cardiology, 133 (4), 233-8
DOI 10.1159/000442249, PubMed 26697854

Laake K, Seljeflot I, Fagerland MW, Njerve IU, Arnesen H, Solheim S (2015)
Effects on serum fractalkine by diet and omega-3 fatty acid intervention: relation to clinical outcome
Mediators Inflamm, 2015, 373070
DOI 10.1155/2015/373070, PubMed 25733777

Pettersen AA, Arnesen H, Seljeflot I (2015)
A brief review on high on-aspirin residual platelet reactivity
Vascul Pharmacol, 67-69, 6-9
DOI 10.1016/j.vph.2015.03.018, PubMed 25869498

Publications 2014

Byrkjeland R, Edvardsen E, Njerve IU, Arnesen H, Seljeflot I, Solheim S (2014)
Insulin levels and HOMA index are associated with exercise capacity in patients with type 2 diabetes and coronary artery disease
Diabetol Metab Syndr, 6 (1), 36
DOI 10.1186/1758-5996-6-36, PubMed 24612649

Bøhmer E, Kristiansen IS, Arnesen H, Halvorsen S (2014)
Health-related quality of life after myocardial infarction, does choice of method make a difference?
Scand Cardiovasc J, 48 (4), 216-22
DOI 10.3109/14017431.2014.923581, PubMed 24828790

Furenes EB, Opstad TB, Solheim S, Lunde K, Arnesen H, Seljeflot I (2014)
The influence of autologous bone marrow stem cell transplantation on matrix metalloproteinases in patients treated for acute ST-elevation myocardial infarction
Mediators Inflamm, 2014, 385901
DOI 10.1155/2014/385901, PubMed 25294955

Helseth R, Seljeflot I, Opstad T, Solheim S, Freynhofer M, Arnesen H, Huber K, Weiss T (2014)
Genes expressed in coronary thrombi are associated with ischemic time in patients with acute myocardial infarction
Thromb Res, 135 (2), 329-33
DOI 10.1016/j.thromres.2014.11.028, PubMed 25496999

Helseth R, Solheim S, Opstad T, Hoffmann P, Arnesen H, Seljeflot I (2014)
The time profile of Pentraxin 3 in patients with acute ST-elevation myocardial infarction and stable angina pectoris undergoing percutaneous coronary intervention
Mediators Inflamm, 2014, 608414
DOI 10.1155/2014/608414, PubMed 24737925

Husebye T, Eritsland J, Arnesen H, Bjørnerheim R, Mangschau A, Seljeflot I, Andersen GØ (2014)
Association of interleukin 8 and myocardial recovery in patients with ST-elevation myocardial infarction complicated by acute heart failure
PLoS One, 9 (11), e112359
DOI 10.1371/journal.pone.0112359, PubMed 25390695

Husted S, de Caterina R, Andreotti F, Arnesen H, Bachmann F, Huber K, Jespersen J, Kristensen SD, Lip GY, Morais J, Rasmussen LH, Siegbahn A, Storey RF, Weitz JI, ESC Working Group on Thrombosis Task Force on Anticoagulants in Heart Disease (2014)
Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel
Thromb Haemost, 111 (5), 781-2
DOI 10.1160/TH14-03-0228, PubMed 24658395

Laake K, Myhre P, Nordby LM, Seljeflot I, Abdelnoor M, Smith P, Tveit A, Arnesen H, Solheim S (2014)
Effects of ω3 supplementation in elderly patients with acute myocardial infarction: design of a prospective randomized placebo controlled study
BMC Geriatr, 14, 74
DOI 10.1186/1471-2318-14-74, PubMed 24928284

Njerve IU, Solheim S, Lunde K, Hoffmann P, Arnesen H, Seljeflot I (2014)
Fractalkine levels are elevated early after PCI-treated ST-elevation myocardial infarction; no influence of autologous bone marrow derived stem cell injection
Cytokine, 69 (1), 131-5
DOI 10.1016/j.cyto.2014.05.022, PubMed 24930044

Opstad TB, Arnesen H, Pettersen AÅ, Seljeflot I (2014)
The MMP-9 -1562 C/T polymorphism in the presence of metabolic syndrome increases the risk of clinical events in patients with coronary artery disease
PLoS One, 9 (9), e106816
DOI 10.1371/journal.pone.0106816, PubMed 25191702

Staff AC, Carlsen KCL, Arnesen H, Bechensteen AG, Jacobsen AF, Omenaas E (2014)
Forskningshåndboken: fra ide til publikasjon
(Carlsen KCL, Staff AC, eds.), Oslo University Hospital, Oslo, 6, 156
PublikaID 222, ISBN 978-82-473-0027-5

Ulimoen SR, Enger S, Norseth J, Pripp AH, Abdelnoor M, Arnesen H, Gjesdal K, Tveit A (2014)
Improved rate control reduces cardiac troponin T levels in permanent atrial fibrillation
Clin Cardiol, 37 (7), 422-7
DOI 10.1002/clc.22281, PubMed 24700386

Wonnerth A, Katsaros KM, Krychtiuk KA, Speidl WS, Kaun C, Thaler K, Huber K, Wojta J, Maurer G, Seljeflot I, Arnesen H, Weiss TW (2014)
Glycoprotein 130 polymorphism predicts soluble glycoprotein 130 levels
Metabolism, 63 (5), 647-53
DOI 10.1016/j.metabol.2014.02.005, PubMed 24629561

Publications 2013

Arnesen H, Seljeflot I (2013)
The challenge of judging data on the effects of N-3 fatty acids in CHD
Scand Cardiovasc J, 47 (2), 67-8
DOI 10.3109/14017431.2012.761348, PubMed 23327650

Berge T, Ulimoen SR, Enger S, Arnesen H, Seljeflot I, Tveit A (2013)
Impact of atrial fibrillation on inflammatory and fibrinolytic variables in the elderly
Scand J Clin Lab Invest, 73 (4), 326-33
DOI 10.3109/00365513.2013.780093, PubMed 23586783

De Caterina R, Husted S, Wallentin L, Andreotti F, Arnesen H, Bachmann F, Baigent C, Huber K, Jespersen J, Kristensen SD, Lip GY, Morais J, Rasmussen LH, Siegbahn A, Verheugt FW, Weitz JI (2013)
Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease
Thromb Haemost, 110 (6), 1087-107
DOI 10.1160/TH13-06-0443, PubMed 24226379

De Caterina R, Husted S, Wallentin L, Andreotti F, Arnesen H, Bachmann F, Baigent C, Huber K, Jespersen J, Kristensen SD, Lip GY, Morais J, Rasmussen LH, Siegbahn A, Verheugt FW, Weitz JI, European Society of Cardiology Working Group on Thrombosis Task Force on Anticoagulants in Heart Disease (2013)
General mechanisms of coagulation and targets of anticoagulants (Section I). Position Paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease
Thromb Haemost, 109 (4), 569-79
DOI 10.1160/TH12-10-0772, PubMed 23447024

De Caterina R, Husted S, Wallentin L, Andreotti F, Arnesen H, Bachmann F, Baigent C, Huber K, Jespersen J, Kristensen SD, Lip GY, Morais J, Rasmussen LH, Siegbahn A, Verheugt FW, Weitz JI, European Society of Cardiology Working Group on Thrombosis Task Force on Anticoagulants in Heart Disease (2013)
Parenteral anticoagulants in heart disease: current status and perspectives (Section II). Position paper of the ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease
Thromb Haemost, 109 (5), 769-86
DOI 10.1160/TH12-06-0403, PubMed 23636477

Grundvold I, Skretteberg PT, Engeseth K, Gjesdal K, Kjeldsen SE, Arnesen H, Bodegard J, Liestøl K, Erikssen G, Erikssen J (2013)
Response to Letter by Morris et al regarding article, "Low heart rates predict incident atrial fibrillation in healthy middle-aged men" by Grundvold et al
Circ Arrhythm Electrophysiol, 6 (6), e102
DOI 10.1161/CIRCEP.113.001154, PubMed 24347602

Grundvold I, Skretteberg PT, Liestøl K, Erikssen G, Engeseth K, Gjesdal K, Kjeldsen SE, Arnesen H, Erikssen J, Bodegard J (2013)
Low heart rates predict incident atrial fibrillation in healthy middle-aged men
Circ Arrhythm Electrophysiol, 6 (4), 726-31
DOI 10.1161/CIRCEP.113.000267, PubMed 23873309

Hopp E, Bjørnerud A, Lunde K, Solheim S, Aakhus S, Arnesen H, Forfang K, Edvardsen T, Smith HJ (2013)
Perfusion MRI at rest in subacute and chronic myocardial infarct
Acta Radiol, 54 (4), 401-11
DOI 10.1177/0284185113475605, PubMed 23401603

Husebye T, Eritsland J, Müller C, Sandvik L, Arnesen H, Seljeflot I, Mangschau A, Bjørnerheim R, Andersen GØ (2013)
Levosimendan in acute heart failure following primary percutaneous coronary intervention-treated acute ST-elevation myocardial infarction. Results from the LEAF trial: a randomized, placebo-controlled study
Eur J Heart Fail, 15 (5), 565-72
DOI 10.1093/eurjhf/hfs215, PubMed 23288914

Opstad TB, Pettersen AÅ, Arnesen H, Seljeflot I (2013)
The co-existence of the IL-18+183 A/G and MMP-9 -1562 C/T polymorphisms is associated with clinical events in coronary artery disease patients
PLoS One, 8 (9), e74498
DOI 10.1371/journal.pone.0074498, PubMed 24040261

Ritschel VN, Seljeflot I, Arnesen H, Halvorsen S, Weiss T, Eritsland J, Andersen GØ (2013)
IL-6 signalling in patients with acute ST-elevation myocardial infarction
Results Immunol, 4, 8-13
DOI 10.1016/j.rinim.2013.11.002, PubMed 24707455

Solheim S, Seljeflot I, Lunde K, Bratseth V, Aakhus S, Forfang K, Arnesen H (2013)
Prothrombotic markers in patients with acute myocardial infarction and left ventricular thrombus formation treated with pci and dual antiplatelet therapy
Thromb J, 11 (1), 1
DOI 10.1186/1477-9560-11-1, PubMed 23311309

Tveit A, Seljeflot I, Smith P, Arnesen H, Svendsen JH (2013)
Angiotensin II blockade, YKL-40 and maintenance of sinus rhythm after electrical cardioversion for atrial fibrillation
Immunobiology, 218 (10), 1256-60
DOI 10.1016/j.imbio.2013.04.014, PubMed 23731775

Ulimoen SR, Enger S, Pripp AH, Abdelnoor M, Arnesen H, Gjesdal K, Tveit A (2013)
Calcium channel blockers improve exercise capacity and reduce N-terminal Pro-B-type natriuretic peptide levels compared with beta-blockers in patients with permanent atrial fibrillation
Eur Heart J, 35 (8), 517-24
DOI 10.1093/eurheartj/eht429, PubMed 24135831

Weiss TW, Arnesen H, Seljeflot I (2013)
Components of the interleukin-6 transsignalling system are associated with the metabolic syndrome, endothelial dysfunction and arterial stiffness
Metabolism, 62 (7), 1008-13
DOI 10.1016/j.metabol.2013.01.019, PubMed 23428306

Publications 2012

Bratseth V, Pettersen AÅ, Opstad TB, Arnesen H, Seljeflot I (2012)
Markers of hypercoagulability in CAD patients. Effects of single aspirin and clopidogrel treatment
Thromb J, 10 (1), 12
DOI 10.1186/1477-9560-10-12, PubMed 22883224

De Caterina R, Husted S, Wallentin L, Andreotti F, Arnesen H, Bachmann F, Baigent C, Huber K, Jespersen J, Kristensen SD, Lip GY, Morais J, Rasmussen LH, Siegbahn A, Verheugt FW, Weitz JI, Coordinating Committee (2012)
New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper
J Am Coll Cardiol, 59 (16), 1413-25
DOI 10.1016/j.jacc.2012.02.008, PubMed 22497820

Grundvold I, Skretteberg PT, Liestøl K, Erikssen G, Kjeldsen SE, Arnesen H, Erikssen J, Bodegard J (2012)
Upper normal blood pressures predict incident atrial fibrillation in healthy middle-aged men: a 35-year follow-up study
Hypertension, 59 (2), 198-204
DOI 10.1161/HYPERTENSIONAHA.111.179713, PubMed 22252392

Grundvold I, Skretteberg PT, Liestøl K, Gjesdal K, Erikssen G, Kjeldsen SE, Arnesen H, Erikssen J, Bodegard J (2012)
Importance of physical fitness on predictive effect of body mass index and weight gain on incident atrial fibrillation in healthy middle-age men
Am J Cardiol, 110 (3), 425-32
DOI 10.1016/j.amjcard.2012.03.043, PubMed 22579085

Halvorsen S, Seljeflot I, Weiss T, Bøhmer E, Arnesen H (2012)
Inflammatory and thrombotic markers in patients with ST-elevation myocardial infarction treated with thrombolysis and early PCI: a NORDISTEMI substudy
Thromb Res, 130 (3), 495-500
DOI 10.1016/j.thromres.2012.04.016, PubMed 22607887

Karlsen A, Svendsen M, Seljeflot I, Laake P, Duttaroy AK, Drevon CA, Arnesen H, Tonstad S, Blomhoff R (2012)
Kiwifruit decreases blood pressure and whole-blood platelet aggregation in male smokers
J Hum Hypertens, 27 (2), 126-30
DOI 10.1038/jhh.2011.116, PubMed 22258209

Lie I, Bunch EH, Smeby NA, Arnesen H, Hamilton G (2012)
Patients' experiences with symptoms and needs in the early rehabilitation phase after coronary artery bypass grafting
Eur J Cardiovasc Nurs, 11 (1), 14-24
DOI 10.1016/j.ejcnurse.2010.09.004, PubMed 21030311

Njerve IU, Pettersen AÅ, Opstad TB, Arnesen H, Seljeflot I (2012)
Fractalkine and its receptor (CX3CR1) in patients with stable coronary artery disease and diabetes mellitus
Metab Syndr Relat Disord, 10 (6), 400-6
DOI 10.1089/met.2012.0052, PubMed 22897138

Pettersen AÅ, Arnesen H, Opstad TB, Bratseth V, Seljeflot I (2012)
Markers of endothelial and platelet activation are associated with high on-aspirin platelet reactivity in patients with stable coronary artery disease
Thromb Res, 130 (3), 424-8
DOI 10.1016/j.thromres.2012.06.016, PubMed 22795340

Pettersen AÅ, Seljeflot I, Abdelnoor M, Arnesen H (2012)
High On-Aspirin Platelet Reactivity and Clinical Outcome in Patients With Stable Coronary Artery Disease: Results From ASCET (Aspirin Nonresponsiveness and Clopidogrel Endpoint Trial)
J Am Heart Assoc, 1 (3), e000703
DOI 10.1161/JAHA.112.000703, PubMed 23130135

Seljeflot I, R Ulimoen S, Enger S, Bratseth V, Arnesen H, Tveit A (2012)
Asymmetric Dimethylarginine Levels are Highly Associated With Atrial Fibrillation in an Elderly Population
Cardiol Res, 3 (3), 109-115
DOI 10.4021/cr175w, PubMed 28352406

Ulimoen SR, Enger S, Carlson J, Platonov PG, Pripp AH, Abdelnoor M, Arnesen H, Gjesdal K, Tveit A (2012)
Comparison of four single-drug regimens on ventricular rate and arrhythmia-related symptoms in patients with permanent atrial fibrillation
Am J Cardiol, 111 (2), 225-30
DOI 10.1016/j.amjcard.2012.09.020, PubMed 23111138

Publications 2011

Bendz B, Endresen K, Eritsland J, Arnesen H (2011)
[Don't withdraw all blood platelet inhibitors]
Tidsskr Nor Laegeforen, 131 (8), 800; author reply 800
DOI 10.4045/tidsskr.11.0278, PubMed 21556070

Byrkjeland R, Nilsson BB, Westheim AS, Arnesen H, Seljeflot I (2011)
Inflammatory markers as related to disease severity in patients with chronic heart failure: limited effects of exercise training
Scand J Clin Lab Invest, 71 (7), 598-605
DOI 10.3109/00365513.2011.598943, PubMed 21831004

Bøhmer E, Kristiansen IS, Arnesen H, Halvorsen S (2011)
Health and cost consequences of early versus late invasive strategy after thrombolysis for acute myocardial infarction
Eur J Cardiovasc Prev Rehabil, 18 (5), 717-23
DOI 10.1177/1741826711398425, PubMed 21450598

Grimsmo J, Maehlum S, Moelstad P, Arnesen H (2011)
Mortality and cardiovascular morbidity among long-term endurance male cross country skiers followed for 28-30 years
Scand J Med Sci Sports, 21 (6), e351-8
DOI 10.1111/j.1600-0838.2011.01307.x, PubMed 21477204

Grøgaard HK, Solheim S, Landsverk KS, Seljeflot I, Hoffmann P, Arnesen H, Ilebekk A (2011)
Circulating CD34⁺ progenitor cells and growth factors in patients treated with PCI for acute myocardial infarction or stable angina pectoris
Scand J Clin Lab Invest, 71 (4), 322-9
DOI 10.3109/00365513.2011.565367, PubMed 21463159

Hopp E, Lunde K, Solheim S, Aakhus S, Arnesen H, Forfang K, Edvardsen T, Smith HJ (2011)
Regional myocardial function after intracoronary bone marrow cell injection in reperfused anterior wall infarction - a cardiovascular magnetic resonance tagging study
J Cardiovasc Magn Reson, 13 (1), 22
DOI 10.1186/1532-429X-13-22, PubMed 21414223

Karlsen A, Svendsen M, Seljeflot I, Sommernes MA, Sexton J, Brevik A, Erlund I, Serafini M, Bastani N, Remberg SF, Borge GI, Carlsen MH, Bøhn SK, Myhrstad MC, Dragsted LO, Duttaroy AK, Haffner K, Laake P, Drevon CA, Arnesen H, Collins A, Tonstad S, Blomhoff R (2011)
Compliance, tolerability and safety of two antioxidant-rich diets: a randomised controlled trial in male smokers
Br J Nutr, 106 (4), 557-71
DOI 10.1017/S0007114511000353, PubMed 21806852

Knudsen EC, Seljeflot I, Abdelnoor M, Eritsland J, Mangschau A, Müller C, Arnesen H, Andersen GO (2011)
Impact of newly diagnosed abnormal glucose regulation on long-term prognosis in low risk patients with ST-elevation myocardial infarction: A follow-up study
BMC Endocr Disord, 11, 14
DOI 10.1186/1472-6823-11-14, PubMed 21801387

Knudsen EC, Seljeflot I, Abdelnoor M, Eritsland J, Mangschau A, Müller C, Arnesen H, Andersen GØ (2011)
Elevated levels of PAI-1 activity and t-PA antigen are associated with newly diagnosed abnormal glucose regulation in patients with ST-elevation myocardial infarction
J Thromb Haemost, 9 (8), 1468-74
DOI 10.1111/j.1538-7836.2011.04377.x, PubMed 21624046

Opstad TB, Pettersen AÅ, Arnesen H, Seljeflot I (2011)
Circulating levels of IL-18 are significantly influenced by the IL-18 +183 A/G polymorphism in coronary artery disease patients with diabetes type 2 and the metabolic syndrome: an observational study
Cardiovasc Diabetol, 10, 110
DOI 10.1186/1475-2840-10-110, PubMed 22141572

Opstad TB, Pettersen AA, Weiss TW, Akra S, Øvstebø R, Arnesen H, Seljeflot I (2011)
Genetic variation, gene-expression and circulating levels of matrix metalloproteinase-9 in patients with stable coronary artery disease
Clin Chim Acta, 413 (1-2), 113-20
DOI 10.1016/j.cca.2011.09.004, PubMed 21963461

Patrono C, Andreotti F, Arnesen H, Badimon L, Baigent C, Collet JP, De Caterina R, Gulba D, Huber K, Husted S, Kristensen SD, Morais J, Neumann FJ, Rasmussen LH, Siegbahn A, Steg PG, Storey RF, Van de Werf F, Verheugt F (2011)
Antiplatelet agents for the treatment and prevention of atherothrombosis
Eur Heart J, 32 (23), 2922-32
DOI 10.1093/eurheartj/ehr373, PubMed 22019823

Pettersen AA, Arnesen H, Opstad TB, Seljeflot I (2011)
The influence of CYP 2C19*2 polymorphism on platelet function testing during single antiplatelet treatment with clopidogrel
Thromb J, 9, 4
DOI 10.1186/1477-9560-9-4, PubMed 21426546

Solheim S, Seljeflot I, Lunde K, Bratseth V, Aakhus S, Forfang K, Arnesen H (2011)
The influence of intracoronary injection of bone marrow cells on prothrombotic markers in patients with acute myocardial infarction
Thromb Res, 130 (5), 765-8
DOI 10.1016/j.thromres.2011.11.045, PubMed 22192151

Steg PG, Huber K, Andreotti F, Arnesen H, Atar D, Badimon L, Bassand JP, De Caterina R, Eikelboom JA, Gulba D, Hamon M, Helft G, Fox KA, Kristensen SD, Rao SV, Verheugt FW, Widimsky P, Zeymer U, Collet JP (2011)
Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology
Eur Heart J, 32 (15), 1854-64
DOI 10.1093/eurheartj/ehr204, PubMed 21715717

Weiss TW, Arnesen H, Trøseid M, Kaun C, Hjerkinn EM, Huber K, Wojta J, Seljeflot I (2011)
Adipose tissue expression of interleukin-18 mRNA is elevated in subjects with metabolic syndrome and independently associated with fasting glucose
Wien Klin Wochenschr, 123 (21-22), 650-4
DOI 10.1007/s00508-011-0028-6, PubMed 21842238

Weiss TW, Seljeflot I, Hjerkinn EM, Arnesen H (2011)
Adipose tissue pro-inflammatory gene expression is associated with cardiovascular disease
Int J Clin Pract, 65 (9), 939-44
DOI 10.1111/j.1742-1241.2011.02717.x, PubMed 21849008

Publications 2010

Arnesen H (2010)
Thrombocardiology: an update
Expert Rev Cardiovasc Ther, 8 (3), 331-3
DOI 10.1586/erc.10.9, PubMed 20222811

Arnesen H, Seljeflot I (2010)
Studies on very long chain marine n-3 fatty acids in patients with atherosclerotic heart disease with special focus on mechanisms, dosage and formulas of supplementation
Cell Mol Biol (Noisy-le-grand), 56 (1), 18-27
DOI 10.1170/T875, PubMed 20196966

Beitnes JO, Gjesdal O, Lunde K, Solheim S, Edvardsen T, Arnesen H, Forfang K, Aakhus S (2010)
Left ventricular systolic and diastolic function improve after acute myocardial infarction treated with acute percutaneous coronary intervention, but are not influenced by intracoronary injection of autologous mononuclear bone marrow cells: a 3 year serial echocardiographic sub-study of the randomized-controlled ASTAMI study
Eur J Echocardiogr, 12 (2), 98-106
DOI 10.1093/ejechocard/jeq116, PubMed 20851818

Bøhmer E, Seljeflot I, Arnesen H, Hoffmann P, Abdelnoor M, Halvorsen S (2010)
The association between metabolic syndrome and infarct size in patients with acute myocardial infarction
Scand J Clin Lab Invest, 70 (4), 287-93
DOI 10.3109/00365513.2010.481819, PubMed 20429699

Bøhn SK, Myhrstad MC, Thoresen M, Holden M, Karlsen A, Tunheim SH, Erlund I, Svendsen M, Seljeflot I, Moskaug JO, Duttaroy AK, Laake P, Arnesen H, Tonstad S, Collins A, Drevon CA, Blomhoff R (2010)
Blood cell gene expression associated with cellular stress defense is modulated by antioxidant-rich food in a randomised controlled clinical trial of male smokers
BMC Med, 8, 54
DOI 10.1186/1741-7015-8-54, PubMed 20846424

Grimsmo J, Arnesen H (2010)
The relationship between exercise and the healthy heart: trouble in paradise?
Expert Rev Cardiovasc Ther, 8 (8), 1047-8
DOI 10.1586/erc.10.69, PubMed 20670180

Grimsmo J, Grundvold I, Maehlum S, Arnesen H (2010)
High prevalence of atrial fibrillation in long-term endurance cross-country skiers: echocardiographic findings and possible predictors--a 28-30 years follow-up study
Eur J Cardiovasc Prev Rehabil, 17 (1), 100-5
DOI 10.1097/HJR.0b013e32833226be, PubMed 20065854

Grimsmo J, Grundvold I, Maehlum S, Arnesen H (2010)
Echocardiographic evaluation of aged male cross country skiers
Scand J Med Sci Sports, 21 (3), 412-9
DOI 10.1111/j.1600-0838.2009.01054.x, PubMed 20136762

Grøgaard HK, Seljeflot I, Lunde K, Solheim S, Aakhus S, Forfang K, Arnesen H, Ilebekk A (2010)
Cell treatment after acute myocardial infarction prevents early decline in circulating IGF-1
Scand Cardiovasc J, 44 (5), 267-72
DOI 10.3109/14017431.2010.490949, PubMed 21080844

Knudsen EC, Seljeflot I, Michael A, Eritsland J, Mangschau A, Müller C, Arnesen H, Andersen GØ (2010)
Increased levels of CRP and MCP-1 are associated with previously unknown abnormal glucose regulation in patients with acute STEMI: a cohort study
Cardiovasc Diabetol, 9, 47
DOI 10.1186/1475-2840-9-47, PubMed 20809989

Lie I, Arnesen H, Sandvik L, Hamilton G, Bunch EH (2010)
Predictors for physical and mental health 6 months after coronary artery bypass grafting: a cohort study
Eur J Cardiovasc Nurs, 9 (4), 238-43
DOI 10.1016/j.ejcnurse.2010.02.001, PubMed 20219433

Lip GY, Huber K, Andreotti F, Arnesen H, Airaksinen JK, Cuisset T, Kirchhof P, Marín F, Consensus Document of European Society of Cardiology Working Group on Thrombosis (2010)
Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: executive summary--a Consensus Document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association (EHRA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)
Eur Heart J, 31 (11), 1311-8
DOI 10.1093/eurheartj/ehq117, PubMed 20447945

Nilsson BB, Westheim A, Risberg MA, Arnesen H, Seljeflot I (2010)
No effect of group-based aerobic interval training on N-terminal pro- B-type natriuretic peptide levels in patients with chronic heart failure
Scand Cardiovasc J, 44 (4), 223-9
DOI 10.3109/14017431.2010.496869, PubMed 20636229

Opstad TB, Pettersen AA, Bratseth V, Arnesen H, Seljeflot I (2010)
The influence of tissue factor and tissue factor pathway inhibitor polymorphisms on thrombin generation in stable coronary artery disease
Pathophysiol Haemost Thromb, 37 (2-4), 98-103
DOI 10.1159/000327491, PubMed 21555871

Opstad TB, Pettersen AA, Weiss T, Arnesen H, Seljeflot I (2010)
Gender differences of polymorphisms in the TF and TFPI genes, as related to phenotypes in patients with coronary heart disease and type-2 diabetes
Thromb J, 8, 7
DOI 10.1186/1477-9560-8-7, PubMed 20444258

Sandset PM, Arnesen H, Jacobsen AF, Wergeland H (2010)
Prophylaxis against prosthetic mitral valve thrombosis with unfractionated heparin administered by an elastometric infusion pump
Thromb Res, 126 (3), e232-4
DOI 10.1016/j.thromres.2010.05.005, PubMed 20553950

Seljeflot I, Nilsson BB, Westheim AS, Bratseth V, Arnesen H (2010)
The L-arginine-asymmetric dimethylarginine ratio is strongly related to the severity of chronic heart failure. No effects of exercise training
J Card Fail, 17 (2), 135-42
DOI 10.1016/j.cardfail.2010.09.003, PubMed 21300303

Solheim S, Seljeflot I, Lunde K, Bjørnerheim R, Aakhus S, Forfang K, Arnesen H (2010)
Frequency of left ventricular thrombus in patients with anterior wall acute myocardial infarction treated with percutaneous coronary intervention and dual antiplatelet therapy
Am J Cardiol, 106 (9), 1197-200
DOI 10.1016/j.amjcard.2010.06.043, PubMed 21029812

Trøseid M, Seljeflot I, Arnesen H (2010)
The role of interleukin-18 in the metabolic syndrome
Cardiovasc Diabetol, 9, 11
DOI 10.1186/1475-2840-9-11, PubMed 20331890

Tveit A, Arnesen H, Smith P, Bratseth V, Seljeflot I (2010)
L-arginine, asymmetric dimethylarginine and rhythm outcome after electrical cardioversion for atrial fibrillation
Cardiology, 117 (3), 176-80
DOI 10.1159/000321402, PubMed 21063118

Weiss TW, Furenes EB, Trøseid M, Solheim S, Hjerkinn EM, Seljeflot I, Arnesen H (2010)
Prediction of cardiovascular events by matrix metalloproteinase (MMP)-9 in elderly men
Thromb Haemost, 103 (3), 679-81
DOI 10.1160/TH09-05-0317, PubMed 20076844

Publications 2009

Beitnes JO, Hopp E, Lunde K, Solheim S, Arnesen H, Brinchmann JE, Forfang K, Aakhus S (2009)
Long-term results after intracoronary injection of autologous mononuclear bone marrow cells in acute myocardial infarction: the ASTAMI randomised, controlled study
Heart, 95 (24), 1983-9
DOI 10.1136/hrt.2009.178913, PubMed 19833610

Bøhmer E, Hoffmann P, Abdelnoor M, Arnesen H, Halvorsen S (2009)
Efficacy and safety of immediate angioplasty versus ischemia-guided management after thrombolysis in acute myocardial infarction in areas with very long transfer distances results of the NORDISTEMI (NORwegian study on DIstrict treatment of ST-elevation myocardial infarction)
J Am Coll Cardiol, 55 (2), 102-10
DOI 10.1016/j.jacc.2009.08.007, PubMed 19747792

Carlsen KCL, Staff A, Arnesen H (2009)
Forskningshåndboken: fra idé til publikasjon
Oslo universitetssykehus, Ullevål i samarbeid med Haukeland universitetssykehus, Oslo (4. utg.), 184 s.
BIBSYS 093919913, ISBN 978-82-473-0022-0

Furenes EB, Arnesen H, Solheim S, Grøgaard HK, Hoffmann P, Seljeflot I (2009)
The profile of circulating metalloproteinases after PCI in patients with acute myocardial infarction or stable angina
Thromb Res, 124 (5), 560-4
DOI 10.1016/j.thromres.2009.04.001, PubMed 19410278

Grimsmo J, Arnesen H, Maehlum S (2009)
Changes in cardiorespiratory function in different groups of former and still active male cross-country skiers: a 28-30-year follow-up study
Scand J Med Sci Sports, 20 (1), e151-61
DOI 10.1111/j.1600-0838.2009.00931.x, PubMed 19422661

Hegbom F, Tveit A, Grundvold I, Arnesen H, Smith P (2009)
Effects of angiotensin receptor blockade on serial P-wave signal-averaged electrocardiograms after electrical cardioversion of persistent atrial fibrillation
Europace, 11 (10), 1301-7
DOI 10.1093/europace/eup220, PubMed 19666643

Knudsen EC, Seljeflot I, Abdelnoor M, Eritsland J, Mangschau A, Arnesen H, Andersen GO (2009)
Abnormal glucose regulation in patients with acute ST- elevation myocardial infarction-a cohort study on 224 patients
Cardiovasc Diabetol, 8, 6
DOI 10.1186/1475-2840-8-6, PubMed 19183453

Kuliczkowski W, Witkowski A, Polonski L, Watala C, Filipiak K, Budaj A, Golanski J, Sitkiewicz D, Pregowski J, Gorski J, Zembala M, Opolski G, Huber K, Arnesen H, Kristensen SD, De Caterina R (2009)
Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology
Eur Heart J, 30 (4), 426-35
DOI 10.1093/eurheartj/ehn562, PubMed 19174428

Lie I, Arnesen H, Sandvik L, Hamilton G, Bunch EH (2009)
Health-related quality of life after coronary artery bypass grafting. The impact of a randomised controlled home-based intervention program
Qual Life Res, 18 (2), 201-7
DOI 10.1007/s11136-008-9438-y, PubMed 19169899

Lip GY, Huber K, Andreotti F, Arnesen H, Airaksinen KJ, Cuisset T, Kirchhof P, Marín F, European Society of Cardiology Working Group on Thrombosis (2009)
Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/ stenting
Thromb Haemost, 103 (1), 13-28
DOI 10.1160/TH09-08-0580, PubMed 20062939

Taraldsrud E, Grøgaard HK, Solheim S, Lunde K, Fløisand Y, Arnesen H, Seljeflot I, Egeland T (2009)
Age and stress related phenotypical changes in bone marrow CD34+ cells
Scand J Clin Lab Invest, 69 (1), 79-84
DOI 10.1080/00365510802419447, PubMed 18836945

Trøseid M, Arnesen H, Hjerkinn EM, Seljeflot I (2009)
Serum levels of interleukin-18 are reduced by diet and n-3 fatty acid intervention in elderly high-risk men
Metabolism, 58 (11), 1543-9
DOI 10.1016/j.metabol.2009.04.031, PubMed 19595382

Trøseid M, Lappegård KT, Mollnes TE, Arnesen H, Seljeflot I (2009)
The effect of exercise on serum levels of interleukin-18 and components of the metabolic syndrome
Metab Syndr Relat Disord, 7 (6), 579-84
DOI 10.1089/met.2009.0003, PubMed 19900154

Trøseid M, Seljeflot I, Weiss TW, Klemsdal TO, Hjerkinn EM, Arnesen H (2009)
Arterial stiffness is independently associated with interleukin-18 and components of the metabolic syndrome
Atherosclerosis, 209 (2), 337-9
DOI 10.1016/j.atherosclerosis.2009.09.028, PubMed 19836750

Tveit A, Bollmann A, Seljeflot I, Husser D, Stridh M, Sörnmo L, Arnesen H, Olsson SB, Smith P (2009)
Relation between atrial fibrillatory rate and markers of inflammation and haemostasis in persistent human atrial fibrillation
Thromb Haemost, 101 (3), 601-3
DOI 10.1160/TH08-07-0482, PubMed 19277431

Publications 2008

Bringager CB, Friis S, Arnesen H, Dammen T (2008)
Nine-year follow-up of panic disorder in chest pain patients: clinical course and predictors of outcome
Gen Hosp Psychiatry, 30 (2), 138-46
DOI 10.1016/j.genhosppsych.2007.12.009, PubMed 18291295

Bringager CB, Gauer K, Arnesen H, Friis S, Dammen T (2008)
Nonfearful panic disorder in chest-pain patients: status after nine-year follow-up
Psychosomatics, 49 (5), 426-37
DOI 10.1176/appi.psy.49.5.426, PubMed 18794512

Brodin E, Seljeflot I, Arnesen H, Hurlen M, Appelbom H, Hansen JB (2008)
Endogenous thrombin potential (ETP) in plasma from patients with AMI during antithrombotic treatment
Thromb Res, 123 (4), 573-9
DOI 10.1016/j.thromres.2008.03.018, PubMed 18474393

Dammen T, Ekeberg Ø, Arnesen H, Friis S (2008)
Health-related quality of life in non-cardiac chest pain patients with and without panic disorder
Int J Psychiatry Med, 38 (3), 271-86
DOI 10.2190/PM.38.3.d, PubMed 19069572

Ellingsen I, Seljeflot I, Arnesen H, Tonstad S (2008)
Vitamin C consumption is associated with less progression in carotid intima media thickness in elderly men: A 3-year intervention study
Nutr Metab Cardiovasc Dis, 19 (1), 8-14
DOI 10.1016/j.numecd.2008.01.006, PubMed 18472409

Furenes EB, Seljeflot I, Solheim S, Hjerkinn EM, Arnesen H (2008)
Long-term influence of diet and/or omega-3 fatty acids on matrix metalloproteinase-9 and pregnancy-associated plasma protein-A in men at high risk of coronary heart disease
Scand J Clin Lab Invest, 68 (3), 177-84
DOI 10.1080/00365510701663350, PubMed 17934973

Grundvold I, Tveit A, Smith P, Seljeflot I, Abdelnoor M, Arnesen H (2008)
The predictive value of transthoracic echocardiographic variables for sinus rhythm maintenance after electrical cardioversion of atrial fibrillation. Results from the CAPRAF study, a prospective, randomized, placebo-controlled study
Cardiology, 111 (1), 30-5
DOI 10.1159/000113424, PubMed 18239389

Haug KBF, Sharikabad MN, Kringen MK, Narum S, Sjaatil ST, Johansen PW, Kierulf P, Seljeflot I, Arnesen H, Brørs O (2008)
Warfarin dose and INR related to genotypes of CYP2C9 and VKORC1 in patients with myocardial infarction
Thromb J, 6, 7
DOI 10.1186/1477-9560-6-7, PubMed 18559094

Hurlen M, Arnesen H (2008)
Oral anticoagulation after myocardial infarction
Herz, 33 (1), 38-43
DOI 10.1007/s00059-008-3074-8, PubMed 18273576

Lunde K, Solheim S, Forfang K, Arnesen H, Brinch L, Bjørnerheim R, Ragnarsson A, Egeland T, Endresen K, Ilebekk A, Mangschau A, Aakhus S (2008)
Anterior myocardial infarction with acute percutaneous coronary intervention and intracoronary injection of autologous mononuclear bone marrow cells: safety, clinical outcome, and serial changes in left ventricular function during 12-months' follow-up
J Am Coll Cardiol, 51 (6), 674-6
DOI 10.1016/j.jacc.2007.10.032, PubMed 18261689

Smith PJ, Hurlen M, Abdelnoor M, Arnesen H (2008)
Less benefit from warfarin in diabetics after myocardial infarction?
Cardiology, 111 (3), 161-6
DOI 10.1159/000121598, PubMed 18434719

Solheim S, Grøgaard HK, Hoffmann P, Arnesen H, Seljeflot I (2008)
Inflammatory responses after percutaneous coronary intervention in patients with acute myocardial infarction or stable angina pectoris
Scand J Clin Lab Invest, 68 (7), 555-62
DOI 10.1080/00365510701884584, PubMed 19378426

Solheim S, Seljeflot I, Lunde K, Aukrust P, Yndestad A, Grøgaard HK, Aakhus S, Forfang K, Arnesen H (2008)
Inflammatory responses after intracoronary injection of autologous mononuclear bone marrow cells in patients with acute myocardial infarction
Am Heart J, 155 (1), 55.e1-9
DOI 10.1016/j.ahj.2007.10.005, PubMed 18082489

Trøseid M, Seljeflot I, Hjerkinn EM, Arnesen H (2008)
Interleukin-18 is a strong predictor of cardiovascular events in elderly men with the metabolic syndrome: synergistic effect of inflammation and hyperglycemia
Diabetes Care, 32 (3), 486-92
DOI 10.2337/dc08-1710, PubMed 19092166

Tveit A, Grundvold I, Olufsen M, Seljeflot I, Abdelnoor M, Arnesen H, Smith P (2008)
Angiotensin receptor blockers in the prevention of atrial fibrillation recurrence: Need for a definitive trial
Int. J. Cardiol., 127 (2), 278-279
DOI 10.1016/j.ijcard.2007.07.044

Tveit A, Seljeflot I, Grundvold I, Abdelnoor M, Arnesen H, Smith P (2008)
Candesartan, NT-proBNP and recurrence of atrial fibrillation after electrical cardioversion
Int J Cardiol, 131 (2), 234-9
DOI 10.1016/j.ijcard.2007.10.028, PubMed 18201783

Publications 2007

Arnesen H, Lunde K, Aakhus S, Forfang K (2007)
Cell therapy in myocardial infarction
Lancet, 369 (9580), 2142-2143
DOI 10.1016/S0140-6736(07)60992-1, PubMed 17604783

Bull Bringager C, Arnesen H, Friis S, Husebye T, Dammen T (2007)
A long-term follow-up study of chest pain patients: effect of panic disorder on mortality, morbidity, and quality of life
Cardiology, 110 (1), 8-14
DOI 10.1159/000109400, PubMed 17934263

Bøhmer E, Arnesen H, Abdelnoor M, Mangschau A, Hoffmann P, Halvorsen S (2007)
The NORwegian study on DIstrict treatment of ST-elevation myocardial infarction (NORDISTEMI)
Scand Cardiovasc J, 41 (1), 32-8
DOI 10.1080/14017430601153472, PubMed 17365975

Carlsen KCL, Staff A, Arnesen H (2007)
Forskningshåndboken: fra idé til publikasjon
Ullevål universitetssykehus i samarbeid med Haukeland universitetssykehus, Oslo (3. utg.), 151 s.
BIBSYS 071048723, ISBN 978-82-473-0019-0

Eid HM, Reims H, Arnesen H, Kjeldsen SE, Lyberg T, Seljeflot I (2007)
Decreased levels of asymmetric dimethylarginine during acute hyperinsulinemia
Metabolism, 56 (4), 464-9
DOI 10.1016/j.metabol.2006.11.003, PubMed 17379002

Ellingsen I, Hjerkinn EM, Seljeflot I, Arnesen H, Tonstad S (2007)
Consumption of fruit and berries is inversely associated with carotid atherosclerosis in elderly men
Br J Nutr, 99 (3), 674-81
DOI 10.1017/S0007114507832521, PubMed 17894919

Jonsson G, Abdelnoor M, Seljeflot I, Arnesen H, Hostmark AT, Kjeldsen SE, Os I, Westheim AS (2007)
The antioxidative effects of long-term treatment are more pronounced for carvedilol than for atenolol in post-myocardial infarction patients
J Cardiovasc Pharmacol, 49 (1), 27-32
DOI 10.1097/FJC.0b013e31802bdd8c, PubMed 17261960

Kjekshus JK, Arnesen H, Gullestad L (2007)
Klinisk forskning: medikamentell behandling
In Det Norske hjerte: norsk hjertemedisins historie, Universitetsforl., Oslo, s. 293-310
BIBSYS 07083086x

Larsen JR, Tsunoda T, Tuzcu EM, Schoenhagen P, Brekke M, Arnesen H, Hanssen KF, Nissen SE, Dahl-Jorgensen K (2007)
Intracoronary ultrasound examinations reveal significantly more advanced coronary atherosclerosis in people with type 1 diabetes than in age- and sex-matched non-diabetic controls
Diab Vasc Dis Res, 4 (1), 62-5
DOI 10.3132/dvdr.2007.009, PubMed 17469046

Lie I, Arnesen H, Sandvik L, Hamilton G, Bunch EH (2007)
Effects of a home-based intervention program on anxiety and depression 6 months after coronary artery bypass grafting: a randomized controlled trial
J Psychosom Res, 62 (4), 411-8
DOI 10.1016/j.jpsychores.2006.11.010, PubMed 17383492

Lunde K, Solheim S, Aakhus S, Arnesen H, Moum T, Abdelnoor M, Egeland T, Endresen K, Ilebekk A, Mangschau A, Forfang K (2007)
Exercise capacity and quality of life after intracoronary injection of autologous mononuclear bone marrow cells in acute myocardial infarction: results from the Autologous Stem cell Transplantation in Acute Myocardial Infarction (ASTAMI) randomized controlled trial
Am Heart J, 154 (4), 710.e1-8
DOI 10.1016/j.ahj.2007.07.003, PubMed 17892996

Nylaende M, Kroese AJ, Morken B, Stranden E, Sandbaek G, Lindahl AK, Arnesen H, Seljeflot I (2007)
Beneficial effects of 1-year optimal medical treatment with and without additional PTA on inflammatory markers of atherosclerosis in patients with PAD. Results from the Oslo Balloon Angioplasty versus Conservative Treatment (OBACT) study
Vasc Med, 12 (4), 275-83
DOI 10.1177/1358863X07082720, PubMed 18048463

Tveit A, Seljeflot I, Grundvold I, Abdelnoor M, Smith P, Arnesen H (2007)
Effect of candesartan and various inflammatory markers on maintenance of sinus rhythm after electrical cardioversion for atrial fibrillation
Am J Cardiol, 99 (11), 1544-8
DOI 10.1016/j.amjcard.2007.01.030, PubMed 17531578

Tveit A, Seljeflot I, Grundvold I, Abdelnoor M, Smith P, Arnesen H (2007)
Levels of PAI-1 and outcome after electrical cardioversion for atrial fibrillation
Thromb Res, 121 (4), 447-53
DOI 10.1016/j.thromres.2007.06.014, PubMed 17698170

Publications 2006

Arnesen H (2006)
In memory of Hans Christian Godal
Thromb. Res., 118 (3), 297-299
DOI 10.1016/j.thromres.2006.01.007

Bethune C, Seierstad SL, Seljeflot I, Johansen O, Arnesen H, Meltzer HM, Rosenlund G, Frøyland L, Lundebye AK (2006)
Dietary intake of differently fed salmon: a preliminary study on contaminants
Eur J Clin Invest, 36 (3), 193-201
DOI 10.1111/j.1365-2362.2006.01612.x, PubMed 16506965

Dammen T, Bringager CB, Arnesen H, Ekeberg O, Friis S (2006)
A 1-year follow-up study of chest-pain patients with and without panic disorder
Gen Hosp Psychiatry, 28 (6), 516-24
DOI 10.1016/j.genhosppsych.2006.08.005, PubMed 17088168

Eid HM, Arnesen H, Hjerkinn EM, Lyberg T, Ellingsen I, Seljeflot I (2006)
Effect of diet and omega-3 fatty acid intervention on asymmetric dimethylarginine
Nutr Metab (Lond), 3, 4
DOI 10.1186/1743-7075-3-4, PubMed 16396682

Eid HM, Lyberg T, Arnesen H, Seljeflot I (2006)
Insulin and adiponectin inhibit the TNFalpha-induced ADMA accumulation in human endothelial cells: the role of DDAH
Atherosclerosis, 194 (2), e1-8
DOI 10.1016/j.atherosclerosis.2006.11.008, PubMed 17141242

Ellingsen I, Hjerkinn EM, Arnesen H, Seljeflot I, Hjermann I, Tonstad S (2006)
Follow-up of diet and cardiovascular risk factors 20 years after cessation of intervention in the Oslo Diet and Antismoking Study
Eur J Clin Nutr, 60 (3), 378-85
DOI 10.1038/sj.ejcn.1602327, PubMed 16306931

Hjerkinn EM, Abdelnoor M, Breivik L, Bergengen L, Ellingsen I, Seljeflot I, Aase O, Ole Klemsdal T, Hjermann I, Arnesen H (2006)
Effect of diet or very long chain omega-3 fatty acids on progression of atherosclerosis, evaluated by carotid plaques, intima-media thickness and by pulse wave propagation in elderly men with hypercholesterolaemia
Eur J Cardiovasc Prev Rehabil, 13 (3), 325-33
DOI 10.1097/01.hjr.0000209817.28444.fb, PubMed 16926660

Lunde K, Solheim S, Aakhus S, Arnesen H, Abdelnoor M, Egeland T, Endresen K, Ilebekk A, Mangschau A, Fjeld JG, Smith HJ, Taraldsrud E, Grøgaard HK, Bjørnerheim R, Brekke M, Müller C, Hopp E, Ragnarsson A, Brinchmann JE, Forfang K (2006)
Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction
N Engl J Med, 355 (12), 1199-209
DOI 10.1056/NEJMoa055706, PubMed 16990383

Nylaende M, Abdelnoor M, Stranden E, Morken B, Sandbaek G, Risum Ø, Jørgensen JJ, Lindahl AK, Arnesen H, Seljeflot I, Kroese AJ (2006)
The Oslo balloon angioplasty versus conservative treatment study (OBACT)--the 2-years results of a single centre, prospective, randomised study in patients with intermittent claudication
Eur J Vasc Endovasc Surg, 33 (1), 3-12
DOI 10.1016/j.ejvs.2006.08.007, PubMed 17055756

Nylaende M, Kroese A, Stranden E, Morken B, Sandbaek G, Lindahl AK, Arnesen H, Seljeflot I (2006)
Prothrombotic activity is associated with the anatomical as well as the functional severity of peripheral arterial occlusive disease
Thromb Haemost, 95 (4), 702-7
DOI 10.1160/TH06-01-0007, PubMed 16601842

Nylaende M, Kroese A, Stranden E, Morken B, Sandbaek G, Lindahl AK, Arnesen H, Seljeflot I (2006)
Markers of vascular inflammation are associated with the extent of atherosclerosis assessed as angiographic score and treadmill walking distances in patients with peripheral arterial occlusive disease
Vasc Med, 11 (1), 21-8
DOI 10.1191/1358863x06vm662oa, PubMed 16669409

Schumacher A, Peersen K, Sommervoll L, Seljeflot I, Arnesen H, Otterstad JE (2006)
Physical performance is associated with markers of vascular inflammation in patients with coronary heart disease
Eur J Cardiovasc Prev Rehabil, 13 (3), 356-62
DOI 10.1097/01.hjr.0000188244.54287.96, PubMed 16926664

Seljeflot I, Larsen JR, Dahl-Jørgensen K, Hanssen KF, Arnesen H (2006)
Fibrinolytic activity is highly influenced by long-term glycemic control in Type 1 diabetic patients
J Thromb Haemost, 4 (3), 686-8
DOI 10.1111/j.1538-7836.2006.01803.x, PubMed 16460457

Solheim S, Pettersen AA, Arnesen H, Seljeflot I (2006)
No difference in the effects of clopidogrel and aspirin on inflammatory markers in patients with coronary heart disease
Thromb Haemost, 96 (5), 660-4
DOI 10.1160/TH06-06-0337, PubMed 17080224

Trøseid M, Hjerkinn EM, Seljeflot I, Klemsdal TO, Bergengen L, Breivik L, Arnesen H (2006)
Comparison of biochemical, functional and structural aspects of arterial wall properties in elderly men
Scand J Clin Lab Invest, 66 (2), 137-45
DOI 10.1080/00365510500474462, PubMed 16537247

Tveit A, Grundvold I, Olufsen M, Seljeflot I, Abdelnoor M, Arnesen H, Smith P (2006)
Candesartan in the prevention of relapsing atrial fibrillation
Int J Cardiol, 120 (1), 85-91
DOI 10.1016/j.ijcard.2006.08.086, PubMed 17113170

Publications 2005

Hjerkinn EM, Seljeflot I, Ellingsen I, Berstad P, Hjermann I, Sandvik L, Arnesen H (2005)
Influence of long-term intervention with dietary counseling, long-chain n-3 fatty acid supplements, or both on circulating markers of endothelial activation in men with long-standing hyperlipidemia
Am J Clin Nutr, 81 (3), 583-9
DOI 10.1093/ajcn/81.3.583, PubMed 15755826

Hjerkinn EM, Seljeflot I, Sandvik L, Hjermann I, Arnesen H (2005)
Markers of endothelial cell activation in elderly men at high risk for coronary heart disease
Scand J Clin Lab Invest, 65 (3), 201-9
DOI 10.1080/00365510510013613, PubMed 16095049

Hurlen M, Eikvar L, Seljeflot I, Arnesen H (2005)
Occult bleeding in three different antithrombotic regimes after myocardial infarction. A WARIS-II subgroup analysis
Thromb Res, 118 (4), 433-8
DOI 10.1016/j.thromres.2005.07.023, PubMed 16139331

Larsen JR, Brekke M, Bergengen L, Sandvik L, Arnesen H, Hanssen KF, Dahl-Jorgensen K (2005)
Mean HbA1c over 18 years predicts carotid intima media thickness in women with type 1 diabetes
Diabetologia, 48 (4), 776-9
DOI 10.1007/s00125-005-1700-z, PubMed 15759107

Lindman AS, Pedersen JI, Arnesen H, Hjerkinn EM, Seljeflot I (2005)
Association between the factor VII haplotype containing the -402A allele and myocardial infarction in a population of elderly men at high risk for coronary heart disease
Thromb Haemost, 94 (1), 226-7
PubMed 16116695

Lindman AS, Pedersen JI, Hjerkinn EM, Veierød MB, Kavlie A, Arnesen H, Seljeflot I (2005)
The influence of the -401G/T and -402G/A polymorphisms of the coagulation FVII promoter on plasma levels of FVII
Thromb Res, 116 (4), 313-20
DOI 10.1016/j.thromres.2004.08.031, PubMed 16038716

Lunde K, Solheim S, Aakhus S, Arnesen H, Abdelnoor M, Forfang K, ASTAMI investigators (2005)
Autologous stem cell transplantation in acute myocardial infarction: The ASTAMI randomized controlled trial. Intracoronary transplantation of autologous mononuclear bone marrow cells, study design and safety aspects
Scand Cardiovasc J, 39 (3), 150-8
DOI 10.1080/14017430510009131, PubMed 16152682

Schmidt EB, Arnesen H, Christensen JH, Rasmussen LH, Kristensen SD, De Caterina R (2005)
Marine n-3 polyunsaturated fatty acids and coronary heart disease: Part II. clinical trials and recommendations
Thromb Res, 115 (4), 257-62
DOI 10.1016/j.thromres.2004.09.007, PubMed 15668184

Schmidt EB, Arnesen H, de Caterina R, Rasmussen LH, Kristensen SD (2005)
Marine n-3 polyunsaturated fatty acids and coronary heart disease. Part I. Background, epidemiology, animal data, effects on risk factors and safety
Thromb Res, 115 (3), 163-70
DOI 10.1016/j.thromres.2004.09.006, PubMed 15617737

Schumacher A, Seljeflot I, Lerkerød AB, Sommervoll L, Otterstad JE, Arnesen H (2005)
Chlamydia LPS and MOMP seropositivity are associated with different cytokine profiles in patients with coronary heart disease
Eur J Clin Invest, 35 (7), 431-7
DOI 10.1111/j.1365-2362.2005.01511.x, PubMed 16008544

Seierstad SL, Seljeflot I, Johansen O, Hansen R, Haugen M, Rosenlund G, Frøyland L, Arnesen H (2005)
Dietary intake of differently fed salmon; the influence on markers of human atherosclerosis
Eur J Clin Invest, 35 (1), 52-9
DOI 10.1111/j.1365-2362.2005.01443.x, PubMed 15638820

Staff A, Carlsen KCL, Arnesen H, Bechensteen AG, Jacobsen AF, Omenaas E, Thorstensen R (2005)
Forskningshåndbok: fra idé til publikasjon
I samarbeid med Kompetansesenter for klinisk forskning, Haukeland universitetssykehus, Oslo (2. utg.), 123 s.
BIBSYS 060317140, ISBN 82-473-0017-6

Trøseid M, Lappegård KT, Mollnes TE, Arnesen H, Seljeflot I (2005)
Changes in serum levels of E-selectin correlate to improved glycaemic control and reduced obesity in subjects with the metabolic syndrome
Scand J Clin Lab Invest, 65 (4), 283-90
DOI 10.1080/00365510510013811, PubMed 16076683

Publications 2004

Arnesen H (2004)
[Norwegian cardiology in 2004]
Tidsskr Nor Laegeforen, 124 (9), 1276
PubMed 15131717

Dammen T, Arnesen H, Ekeberg O, Friis S (2004)
Psychological factors, pain attribution and medical morbidity in chest-pain patients with and without coronary artery disease
Gen Hosp Psychiatry, 26 (6), 463-9
DOI 10.1016/j.genhosppsych.2004.08.004, PubMed 15567212

Eid HM, Arnesen H, Hjerkinn EM, Lyberg T, Seljeflot I (2004)
Relationship between obesity, smoking, and the endogenous nitric oxide synthase inhibitor, asymmetric dimethylarginine
Metabolism, 53 (12), 1574-9
DOI 10.1016/j.metabol.2004.06.026, PubMed 15562402

Eritsland J, Arnesen H (2004)
[Secondary prophylaxis after myocardial infarction, bypass surgery and percutaneous coronary intervention]
Tidsskr Nor Laegeforen, 124 (7), 946-9
PubMed 15060643

Hjerkinn EM, Sandvik L, Hjermann I, Arnesen H (2004)
Effect of diet intervention on long-term mortality in healthy middle-aged men with combined hyperlipidaemia
J Intern Med, 255 (1), 68-73
DOI 10.1046/j.0954-6820.2003.01248.x, PubMed 14687240

Johansen O, Brekke M, Seljeflot I, Semb AG, Arnesen H (2004)
Blood platelet count and reactivity are associated with restenosis 6 months after coronary angioplasty
Scand Cardiovasc J, 38 (4), 211-5
DOI 10.1080/14017430410035494, PubMed 15553931

Johansen O, Brekke M, Seljeflot I, Semb AGP, Arnesen H (2004)
Blood platelet count and reactivity are associated with restenosis 6 months after coronary angioplasty
In Scandinavian cardiovascular journal, Taylor & Francis, Stockholm, 38(2004)4, S. 211-215
BIBSYS 051805693

Lindman AS, Pedersen JI, Arnesen H, Hjerkinn EM, Veierød MB, Prydz H, Seljeflot I (2004)
Coagulation factor VII, R353Q polymorphism, and serum choline-containing phospholipids in males at high risk for coronary heart disease
Thromb Res, 113 (1), 57-65
DOI 10.1016/j.thromres.2004.02.001, PubMed 15081566

Lindman AS, Pedersen JI, Hjerkinn EM, Arnesen H, Veierød MB, Ellingsen I, Seljeflot I (2004)
The effects of long-term diet and omega-3 fatty acid supplementation on coagulation factor VII and serum phospholipids with special emphasis on the R353Q polymorphism of the FVII gene
Thromb Haemost, 91 (6), 1097-104
DOI 10.1160/TH03-12-0773, PubMed 15175795

Mansoor MA, Seljeflot I, Arnesen H, Knudsen A, Bates CJ, Mishra G, Larsen TW (2004)
Endothelial cell adhesion molecules in healthy adults during acute hyperhomocysteinemia and mild hypertriglyceridemia
Clin Biochem, 37 (5), 408-14
DOI 10.1016/j.clinbiochem.2004.01.003, PubMed 15087258

Pettersen AA, Seljeflot I, Abdelnoor M, Arnesen H (2004)
Unstable angina, stroke, myocardial infarction and death in aspirin non-responders. A prospective, randomized trial. The ASCET (ASpirin non-responsiveness and Clopidogrel Endpoint Trial) design
Scand Cardiovasc J, 38 (6), 353-6
DOI 10.1080/14017430410024324, PubMed 15804802

Seljeflot I, Hurlen M, Arnesen H (2004)
Increased levels of soluble tissue factor during long-term treatment with warfarin in patients after an acute myocardial infarction
J Thromb Haemost, 2 (5), 726-30
DOI 10.1111/j.1538-7836.2004.00676.x, PubMed 15099277

Seljeflot I, Hurlen M, Solheim S, Arnesen H (2004)
Serum levels of interleukin-10 are inversely related to future events in patients with acute myocardial infarction
J Thromb Haemost, 2 (2), 350-2
DOI 10.1111/j.1538-7933.2004.0584c.x, PubMed 14996010

Seljeflot I, Lyberg T, Arnesen H (2004)
Soluble tissue factor in plasma from patients with acute myocardial infarction is not microvesicle-associated
PROCEEDINGS OF THE 18TH INTERNATIONAL CONGRESS ON THROMBOSIS, 11-15

Skjaeggestad Ø, Johansen O, Arnesen H (2004)
[Exercise ECG and localization of coronary artery stenoses]
Tidsskr Nor Laegeforen, 124 (23), 3066-8
PubMed 15586190

Publications 2003

Arnesen H (2003)
Oral anticoagulation after myocardial infarction
Thromb Res, 109 (4), 163-70
DOI 10.1016/s0049-3848(03)00181-6, PubMed 12757769

Arnesen H, Dahl OE, Aspelin T, Seljeflot I, Kierulf P, Lyberg T (2003)
Sustained prothrombotic profile after hip replacement surgery: the influence of prolonged prophylaxis with dalteparin
J Thromb Haemost, 1 (5), 971-5
DOI 10.1046/j.1538-7836.2003.00111.x, PubMed 12871363

Berstad P, Seljeflot I, Veierød MB, Hjerkinn EM, Arnesen H, Pedersen JI (2003)
Supplementation with fish oil affects the association between very long-chain n-3 polyunsaturated fatty acids in serum non-esterified fatty acids and soluble vascular cell adhesion molecule-1
Clin Sci (Lond), 105 (1), 13-20
DOI 10.1042/CS20020349, PubMed 12589702

Carlsen KCL, Staff A, Arnesen H, Bechensteen AG, Jacobsen AF, Omenaas E (2003)
Forskningshåndbok: fra idé til publikasjon
Vitenskapsrådet Ullevål universitetssykehus HF, Oslo, 89 s.
BIBSYS 040620689, ISBN 82-473-0017-6

Eid HM, Eritsland J, Larsen J, Arnesen H, Seljeflot I (2003)
Increased levels of asymmetric dimethylarginine in populations at risk for atherosclerotic disease. Effects of pravastatin
Atherosclerosis, 166 (2), 279-84
DOI 10.1016/s0021-9150(02)00206-x, PubMed 12535740

Hjerkinn EM, Sandvik L, Hjermann I, Arnesen H (2003)
Fasting triglycerides as a predictor of long-term mortality in middle-aged men with combined hyperlipidaemia
Scand J Clin Lab Invest, 63 (4), 273-8
DOI 10.1080/00365510310001672, PubMed 12940635

Hurlen M, Arnesen H, Smith P (2003)
Warfarin, aspirin, or both after myocardial infarction - Reply
N. Engl. J. Med., 348 (3), 257

Larsen J, Bergengen L, Sandvik L, Arnesen H, Hanssen KF, Dahl-Jørgensen K (2003)
Mean HbA1c during 18 years predicts common cartoid arteryintima-media thickness in women with diabetes type 1
In Diabetes, The Association, New York, 52(2003)suppl 1, s.P687
BIBSYS 041734599

Seljeflot I, Hurlen M, Hole T, Arnesen H (2003)
Soluble tissue factor as predictor of future events in patients with acute myocardial infarction
Thromb Res, 111 (6), 369-72
DOI 10.1016/j.thromres.2003.09.019, PubMed 14698655

Solheim S, Arnesen H, Eikvar L, Hurlen M, Seljeflot I (2003)
Influence of aspirin on inflammatory markers in patients after acute myocardial infarction
Am J Cardiol, 92 (7), 843-5
DOI 10.1016/s0002-9149(03)00897-x, PubMed 14516890

Publications 2002

Andersen K, Hurlen M, Arnesen H, Seljeflot I (2002)
Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease
Thromb Res, 108 (1), 37-42
DOI 10.1016/s0049-3848(02)00405-x, PubMed 12586130

Eid HM, Lyberg T, Larsen J, Arnesen H, Seljeflot I (2002)
Reactive oxygen species generation by leukocytes in populations at risk for atherosclerotic disease
Scand J Clin Lab Invest, 62 (6), 431-9
DOI 10.1080/00365510260389985, PubMed 12469898

Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H (2002)
Warfarin, aspirin, or both after myocardial infarction
N Engl J Med, 347 (13), 969-74
DOI 10.1056/NEJMoa020496, PubMed 12324552

Larsen J, Brekke M, Sandvik L, Arnesen H, Hanssen KF, Dahl-Jorgensen K (2002)
Silent coronary atheromatosis in type 1 diabetic patients and its relation to long-term glycemic control
Diabetes, 51 (8), 2637-41
DOI 10.2337/diabetes.51.8.2637, PubMed 12145181

Olesen M, Kwong E, Meztli A, Kontny F, Seljeflot I, Arnesen H, Lyngdorf L, Falk E (2002)
No effect of cyclooxygenase inhibition on plaque size in atherosclerosis-prone mice
Scand Cardiovasc J, 36 (6), 362-7
DOI 10.1080/140174302762659094, PubMed 12626204

Schumacher A, Seljeflot I, Lerkerød AB, Sommervoll L, Otterstad JE, Arnesen H (2002)
Positive Chlamydia pneumoniae serology is associated with elevated levels of tumor necrosis factor alpha in patients with coronary heart disease
Atherosclerosis, 164 (1), 153-60
DOI 10.1016/s0021-9150(02)00043-6, PubMed 12119204

Schumacher A, Seljeflot I, Lerkerød AB, Sommervoll L, Otterstad JE, Arnesen H (2002)
Does infection with Chlamydia pneumoniae and/or Helicobacter pylori increase the expression of endothelial cell adhesion molecules in humans?
Clin Microbiol Infect, 8 (10), 654-61
DOI 10.1046/j.1469-0691.2002.00439.x, PubMed 12390284

Schumacher A, Seljeflot I, Sommervoll L, Christensen B, Otterstad JE, Arnesen H (2002)
Increased levels of endothelial haemostatic markers in patients with coronary heart disease
Thromb Res, 105 (1), 25-31
DOI 10.1016/s0049-3848(01)00399-1, PubMed 11864703

Schumacher A, Seljeflot I, Sommervoll L, Christensen B, Otterstad JE, Arnesen H (2002)
Increased levels of markers of vascular inflammation in patients with coronary heart disease
Scand J Clin Lab Invest, 62 (1), 59-68
DOI 10.1080/003655102753517217, PubMed 12002414

Seljeflot I, Tonstad S, Hjermann I, Arnesen H (2002)
Reduced expression of endothelial cell markers after 1 year treatment with simvastatin and atorvastatin in patients with coronary heart disease
Atherosclerosis, 162 (1), 179-85
DOI 10.1016/s0021-9150(01)00696-7, PubMed 11947912

Seljeflot I, Tonstad S, Hjermann I, Arnesen H (2002)
Improved fibrinolysis after 1-year treatment with HMG CoA reductase inhibitors in patients with coronary heart disease
Thromb Res, 105 (4), 285-90
DOI 10.1016/s0049-3848(02)00034-8, PubMed 12031821

Seljeflot L, Hurlen M, Christensen B, Fjeldly M, Klaeboe LG, Arnesen H (2002)
Homocysteine as predictor of clinical events in patients with previous myocardial infarction
ATHEROSCLEROSIS: RISK FACTORS, DIAGNOSIS, AND TREATMENT, 197-201

Yli-Jama P, Seljeflot I, Meyer HE, Hjerkinn EM, Arnesen H, Pedersen JI (2002)
Serum non-esterified very long-chain PUFA are associated with markers of endothelial dysfunction
Atherosclerosis, 164 (2), 275-81
DOI 10.1016/s0021-9150(02)00067-9, PubMed 12204798

Publications 2001

Ackermann KH, Adams N, Adler C, Ahammed Z, Ahmad S, Allgower C, Amsbaugh J, Anderson M, Anderssen E, Arnesen H, Arnold L, Averichev GS, Baldwin A, Balewski J, Barannikova O, Barnby LS, Baudot J, Beddo M, Bekele S, Belaga VV, Bellwied R, Bennett S, Bercovitz J, Berger J, Betts W et al. (2001)
Elliptic flow in Au+Au collisions at square root(S)NN = 130 GeV
Phys Rev Lett, 86 (3), 402-7
DOI 10.1103/PhysRevLett.86.402, PubMed 11177841

Arnesen H (2001)
n-3 fatty acids and revascularization procedures
Lipids, 36 Suppl, S103-6
DOI 10.1007/s11745-001-0690-z, PubMed 11837981

Guzic-Salobir B, Keber I, Seljeflot I, Arnesen H, Vrabic L (2001)
Combined hormone replacement therapy improves endothelial function in healthy postmenopausal women
J Intern Med, 250 (6), 508-15
DOI 10.1046/j.1365-2796.2001.00910.x, PubMed 11902819

Hurlen M, Hole T, Seljeflot I, Arnesen H (2001)
Aspirin does not influence the effect of angiotensin-converting enzyme inhibition on left ventricular ejection fraction 3 months after acute myocardial infarction
Eur J Heart Fail, 3 (2), 203-7
DOI 10.1016/s1388-9842(00)00138-0, PubMed 11246058

Johansen O, Abdelnoor M, Brekke M, Seljeflot I, Høstmark AT, Arnesen H (2001)
Predictors of restenosis after coronary angioplasty. A study on demographic and metabolic variables
Scand Cardiovasc J, 35 (2), 86-91
DOI 10.1080/140174301750164691, PubMed 11405502

Nordøy A, Marchioli R, Arnesen H, Videbaek J (2001)
n-3 polyunsaturated fatty acids and cardiovascular diseases
Lipids, 36 Suppl, S127-9
DOI 10.1007/s11745-001-0695-7, PubMed 11837986

Schumacher A, Lerkerød AB, Seljeflot I, Sommervoll L, Holme I, Otterstad JE, Arnesen H (2001)
Chlamydia pneumoniae serology: importance of methodology in patients with coronary heart disease and healthy individuals
J Clin Microbiol, 39 (5), 1859-64
DOI 10.1128/JCM.39.5.1859-1864.2001, PubMed 11326004

Solheim S, Seljeflot I, Arnesen H, Eritsland J, Eikvar L (2001)
Reduced levels of TNF alpha in hypercholesterolemic individuals after treatment with pravastatin for 8 weeks
Atherosclerosis, 157 (2), 411-5
DOI 10.1016/s0021-9150(00)00725-5, PubMed 11472741

Publications 2000

Arnesen H (2000)
[Oral anticoagulation--a good prophylaxis requiring check up]
Tidsskr Nor Laegeforen, 120 (16), 1845
PubMed 10925606

Dammen T, Arnesen H (2000)
Mitral valve prolapse versus panic disorder in patients with chest pain - Reply
J. Intern. Med., 247 (4), 518-519

Dammen T, Ekeberg O, Arnesen H, Friis S (2000)
Personality profiles in patients referred for chest pain. Investigation with emphasis on panic disorder patients
Psychosomatics, 41 (3), 269-76
DOI 10.1176/appi.psy.41.3.269, PubMed 10849460

Hurlen M, Seljeflot I, Arnesen H (2000)
Increased platelet aggregability during exercise in patients with previous myocardial infarction. Lack of inhibition by aspirin
Thromb Res, 99 (5), 487-94
DOI 10.1016/s0049-3848(00)00277-2, PubMed 10973679

Hurlen M, Smith P, Arnesen H (2000)
Effects of warfarin, aspirin and the two combined, on mortality and thromboembolic morbidity after myocardial infarction. The WARIS-II (Warfarin-Aspirin Reinfarction Study) design
Scand Cardiovasc J, 34 (2), 168-71
DOI 10.1080/14017430050142198, PubMed 10872704

Høibraaten E, Qvigstad E, Arnesen H, Larsen S, Wickstrøm E, Sandset PM (2000)
Increased risk of recurrent venous thromboembolism during hormone replacement therapy--results of the randomized, double-blind, placebo-controlled estrogen in venous thromboembolism trial (EVTET)
Thromb Haemost, 84 (6), 961-7
PubMed 11154141

Seljeflot I, Arnesen H, Hofstad AE, Os I (2000)
Reduced expression of endothelial cell markers after long-term transdermal hormone replacement therapy in women with coronary artery disease
Thromb Haemost, 83 (6), 944-8
PubMed 10896253

Publications 1999

Brude IR, Finstad HS, Seljeflot I, Drevon CA, Solvoll K, Sandstad B, Hjermann I, Arnesen H, Nenseter MS (1999)
Plasma homocysteine concentration related to diet, endothelial function and mononuclear cell gene expression among male hyperlipidaemic smokers
Eur J Clin Invest, 29 (2), 100-8
DOI 10.1046/j.1365-2362.1999.00419.x, PubMed 10092996

Dahl OE, Walsoe HK, Aspelin T, Roise O, Arnesen H, Lyberg T (1999)
Combined administration of dextran 70 and dalteparin does not increase perioperative blood loss compared to dextran 70 alone in major orthopedic surgery
Haemostasis, 29 (5), 262-8
DOI 10.1159/000022511, PubMed 10754378

Dammen T, Arnesen H, Ekeberg O, Husebye T, Friis S (1999)
Panic disorder in chest pain patients referred for cardiological outpatient investigation
J Intern Med, 245 (5), 497-507
DOI 10.1046/j.1365-2796.1999.00447.x, PubMed 10363751

Dammen T, Ekeberg O, Arnesen H, Friis S (1999)
The detection of panic disorder in chest pain patients
Gen Hosp Psychiatry, 21 (5), 323-32
DOI 10.1016/s0163-8343(99)00037-7, PubMed 10572773

Halvorsen S, Husebye T, Arnesen H (1999)
Prosthetic heart valve thrombosis during dicloxacillin therapy
Scand Cardiovasc J, 33 (6), 366-8
DOI 10.1080/14017439950141443, PubMed 10622550

Johansen O, Brekke M, Seljeflot I, Abdelnoor M, Arnesen H (1999)
N-3 fatty acids do not prevent restenosis after coronary angioplasty: results from the CART study. Coronary Angioplasty Restenosis Trial
J Am Coll Cardiol, 33 (6), 1619-26
DOI 10.1016/s0735-1097(99)00054-6, PubMed 10334433

Johansen O, Seljeflot I, Høstmark AT, Arnesen H (1999)
The effect of supplementation with omega-3 fatty acids on soluble markers of endothelial function in patients with coronary heart disease
Arterioscler Thromb Vasc Biol, 19 (7), 1681-6
DOI 10.1161/01.atv.19.7.1681, PubMed 10397685

Seljeflot I, Arnesen H, Andersen P, Aspelin T, Kierulf P (1999)
Effects of doxazosin and atenolol on circulating endothelin-1 and von Willebrand factor in hypertensive middle-aged men
J Cardiovasc Pharmacol, 34 (4), 584-8
DOI 10.1097/00005344-199910000-00016, PubMed 10511135

Seljeflot I, Johansen O, Arnesen H, Eggesbø JB, Westvik AB, Kierulf P (1999)
Procoagulant activity and cytokine expression in whole blood cultures from patients with atherosclerosis supplemented with omega-3 fatty acids
Thromb Haemost, 81 (4), 566-70
PubMed 10235440

Publications 1998

Andersen P, Seljeflot I, Herzog A, Arnesen H, Hjermann I, Holme I (1998)
Effects of doxazosin and atenolol on atherothrombogenic risk profile in hypertensive middle-aged men
J Cardiovasc Pharmacol, 31 (5), 677-83
DOI 10.1097/00005344-199805000-00005, PubMed 9593066

Arnesen H, Sandset PM (1998)
[Peroral anticoagulant therapy]
Tidsskr Nor Laegeforen, 118 (18), 2824
PubMed 9748818

Hurlen M, Seljeflot I, Arnesen H (1998)
The effect of different antithrombotic regimens on platelet aggregation after myocardial infarction
Scand Cardiovasc J, 32 (4), 233-7
DOI 10.1080/14017439850140021, PubMed 9802142

Ilebekk A, Arnesen H (1998)
[Transient postischemic myocardial injury--a condition of practical clinical significance?]
Tidsskr Nor Laegeforen, 118 (5), 745-8
PubMed 9528373

Johansen O, Brekke M, Strømme JH, Valen V, Seljeflot I, Skjaeggestad O, Arnesen H (1998)
Myocardial damage during percutaneous transluminal coronary angioplasty as evidenced by troponin T measurements
Eur Heart J, 19 (1), 112-7
DOI 10.1053/euhj.1997.0732, PubMed 9503183

Seljeflot I, Arnesen H, Brude IR, Nenseter MS, Drevon CA, Hjermann I (1998)
Effects of omega-3 fatty acids and/or antioxidants on endothelial cell markers
Eur J Clin Invest, 28 (8), 629-35
DOI 10.1046/j.1365-2362.1998.00336.x, PubMed 9767357

Seljeflot I, Moan A, Aspelin T, Tønnessen T, Kjeldsen SE, Arnesen H (1998)
Circulating levels of endothelin-1 during acute hyperinsulinemia in patients with essential hypertension treated with type 1 angiotensin receptor antagonist or placebo
Metabolism, 47 (3), 292-6
DOI 10.1016/s0026-0495(98)90259-1, PubMed 9500565

Strømme JH, Johansen O, Brekke M, Seljeflot I, Arnesen H (1998)
Markers of myocardial injury in blood following PTCA: a comparison of CKMB, cardiospecific troponin T and troponin I
Scand J Clin Lab Invest, 58 (8), 693-9
DOI 10.1080/00365519850186139, PubMed 10088207

Publications 1997

Arnesen H, Qvigstad E (1997)
[Postmenopausal hormonal substitution and risk of venous thromboembolism. Need for prospective, randomized trials]
Tidsskr Nor Laegeforen, 117 (28), 4064
PubMed 9441436

Brude IR, Drevon CA, Hjermann I, Seljeflot I, Lund-Katz S, Saarem K, Sandstad B, Solvoll K, Halvorsen B, Arnesen H, Nenseter MS (1997)
Peroxidation of LDL from combined-hyperlipidemic male smokers supplied with omega-3 fatty acids and antioxidants
Arterioscler Thromb Vasc Biol, 17 (11), 2576-88
DOI 10.1161/01.atv.17.11.2576, PubMed 9409230

Dahl OE, Andreassen G, Aspelin T, Müller C, Mathiesen P, Nyhus S, Abdelnoor M, Solhaug JH, Arnesen H (1997)
Prolonged thromboprophylaxis following hip replacement surgery--results of a double-blind, prospective, randomised, placebo-controlled study with dalteparin (Fragmin)
Thromb Haemost, 77 (1), 26-31
PubMed 9031444

Publications 1996

Eritsland J, Arnesen H, Grønseth K, Fjeld NB, Abdelnoor M (1996)
Effect of dietary supplementation with n-3 fatty acids on coronary artery bypass graft patency
Am J Cardiol, 77 (1), 31-6
DOI 10.1016/s0002-9149(97)89130-8, PubMed 8540453

Moan A, Høieggen A, Seljeflot I, Risanger T, Arnesen H, Kjeldsen SE (1996)
The effect of angiotensin II receptor antagonism with losartan on glucose metabolism and insulin sensitivity
J Hypertens, 14 (9), 1093-7
DOI 10.1097/00004872-199609000-00008, PubMed 8986909

Seljeflot I, Moan A, Kjeldsen S, Sandvik E, Arnesen H (1996)
Effect of angiotensin II receptor blockade on fibrinolysis during acute hyperinsulinemia in patients with essential hypertension
Hypertension, 27 (6), 1299-304
DOI 10.1161/01.hyp.27.6.1299, PubMed 8641739

Steine S, Laerum E, Eritsland J, Arnesen H (1996)
Predictors of enhanced well-being after coronary artery bypass surgery
J Intern Med, 239 (1), 69-73
DOI 10.1046/j.1365-2796.1996.425768000.x, PubMed 8551203

Publications 1995

Andersen P, Seljeflot I, Abdelnoor M, Arnesen H, Dale PO, Løvik A, Birkeland K (1995)
Increased insulin sensitivity and fibrinolytic capacity after dietary intervention in obese women with polycystic ovary syndrome
Metabolism, 44 (5), 611-6
DOI 10.1016/0026-0495(95)90118-3, PubMed 7752909

Arnesen H, Sandset PM, Eritsland J (1995)
[Fat-soluble vitamins in clinical practice]
Tidsskr Nor Laegeforen, 115 (7), 870
PubMed 7701499

Dahl OE, Aspelin T, Arnesen H, Seljeflot I, Kierulf P, Ruyter R, Lyberg T (1995)
Increased activation of coagulation and formation of late deep venous thrombosis following discontinuation of thromboprophylaxis after hip replacement surgery
Thromb Res, 80 (4), 299-306
DOI 10.1016/0049-3848(95)00180-y, PubMed 8585042

Eritsland J, Arnesen H, Berg K, Seljeflot I, Abdelnoor M (1995)
Serum Lp(a) lipoprotein levels in patients with coronary artery disease and the influence of long-term n-3 fatty acid supplementation
Scand J Clin Lab Invest, 55 (4), 295-300
DOI 10.3109/00365519509104966, PubMed 7569731

Eritsland J, Arnesen H, Fjeld NB, Grønseth K, Abdelnoor M (1995)
Risk factors for graft occlusion after coronary artery bypass grafting
Scand J Thorac Cardiovasc Surg, 29 (2), 63-9
DOI 10.3109/14017439509107204, PubMed 8643928

Eritsland J, Arnesen H, Seljeflot I, Høstmark AT (1995)
Long-term metabolic effects of n-3 polyunsaturated fatty acids in patients with coronary artery disease
Am J Clin Nutr, 61 (4), 831-6
DOI 10.1093/ajcn/61.4.831, PubMed 7702027

Eritsland J, Arnesen H, Seljeflot I, Kierulf P (1995)
Long-term effects of n-3 polyunsaturated fatty acids on haemostatic variables and bleeding episodes in patients with coronary artery disease
Blood Coagul Fibrinolysis, 6 (1), 17-22
DOI 10.1097/00001721-199502000-00003, PubMed 7795149

Eritsland J, Gjønnes G, Sandset PM, Seljeflot I, Arnesen H (1995)
Activated protein C resistance and graft occlusion after coronary artery bypass surgery
Thromb Res, 79 (2), 223-6
DOI 10.1016/0049-3848(95)91526-q, PubMed 7676409

Eritsland J, Seljeflot I, Arnesen H, Westvik AB, Kierulf P (1995)
Effect of long-term, moderate-dose supplementation with omega-3 fatty acids on monocyte procoagulant activity and release of interleukin-6 in patients with coronary artery disease
Thromb Res, 77 (4), 337-46
DOI 10.1016/0049-3848(95)93837-p, PubMed 7740525

SELJEFLOT I, ARNESEN H, STOEN R, LYBERG T (1995)
EFFECTS OF INSULIN AND SOME VASOCONSTRICTORS ON THE SYNTHESIS AND RELEASE OF T-PA AND PAI-1 FROM CULTURED HUMAN UMBILICAL VEIN ENDOTHELIAL-CELLS
Fibrinolysis, 9 (4), 253-257
DOI 10.1016/S0268-9499(08)80068-9

Publications 1994

Arnesen H (1994)
[Coronary heart disease in the age of technology]
Tidsskr Nor Laegeforen, 114 (29), 3413-4
PubMed 7998038

Arnesen H (1994)
[Unscientific use of scientific data?]
Tidsskr Nor Laegeforen, 114 (4), 419-20
PubMed 8009471

Eikvar L, Pillgram-Larsen J, Skjaeggestad O, Arnesen H, Strømme JH (1994)
Serum cardio-specific troponin T after open heart surgery in patients with and without perioperative myocardial infarction
Scand J Clin Lab Invest, 54 (4), 329-35
DOI 10.3109/00365519409087530, PubMed 7939377

Eritsland J, Arnesen H, Seljeflot I, Abdelnoor M, Grønseth K, Berg K, Malinow MR (1994)
Influence of serum lipoprotein(a) and homocyst(e)ine levels on graft patency after coronary artery bypass grafting
Am J Cardiol, 74 (11), 1099-102
DOI 10.1016/0002-9149(94)90459-6, PubMed 7977066

ERITSLAND J, SELJEFLOT I, ABDELNOOR M, ARNESEN H (1994)
LONG-TERM INFLUENCE OF OMEGA-3-FATTY-ACIDS ON FIBRINOLYSIS, FIBRINOGEN, AND SERUM-LIPIDS
Fibrinolysis, 8 (2), 120-125
DOI 10.1016/S0268-9499(05)80029-3

Eritsland J, Seljeflot I, Abdelnoor M, Arnesen H, Torjesen PA (1994)
Long-term effects of n-3 fatty acids on serum lipids and glycaemic control
Scand J Clin Lab Invest, 54 (4), 273-80
DOI 10.3109/00365519409087522, PubMed 7939369

Hurlen M, Erikssen J, Smith P, Arnesen H, Rollag A (1994)
Comparison of bleeding complications of warfarin and warfarin plus acetylsalicylic acid: a study in 3166 outpatients
J Intern Med, 236 (3), 299-304
DOI 10.1111/j.1365-2796.1994.tb00800.x, PubMed 8077887

Seljeflot I, Eritsland J, Andersen P, Arnesen H (1994)
Global fibrinolytic capacity assessed by the serum D-dimer test. Correlation between basal and stimulated values
Thromb Res, 75 (2), 157-62
DOI 10.1016/0049-3848(94)90064-7, PubMed 7974389

Seljeflot I, Eritsland J, Torjesen P, Arnesen H (1994)
Insulin and PAI-1 levels during oral glucose tolerance test in patients with coronary heart disease
Scand J Clin Lab Invest, 54 (3), 241-6
DOI 10.3109/00365519409088431, PubMed 8036449

Seljeflot I, Haaland AH, Arnesen H (1994)
Stability of plasma PAI-I at room temperature
Thromb Res, 73 (1), 75-8
DOI 10.1016/0049-3848(94)90056-6, PubMed 8178316

Publications 1993

Dahl OE, Pedersen T, Kierulf P, Westvik AB, Lund P, Arnesen H, Seljeflot I, Abdelnoor M, Lyberg T (1993)
Sequential intrapulmonary and systemic activation of coagulation and fibrinolysis during and after total hip replacement surgery
Thromb Res, 70 (6), 451-8
DOI 10.1016/0049-3848(93)90087-5, PubMed 8362370

SELJEFLOT I, ARNESEN H, ERITSLAND J, SMITH P (1993)
D-DIMER TEST AFTER STANDARDIZED COAGULATION - A NEW ASSAY FOR GLOBAL EVALUATION OF THE UNSTIMULATED FIBRINOLYTIC SYSTEM
Fibrinolysis, 7 (5), 303-307
DOI 10.1016/0268-9499(93)90145-L

Publications 1992

Arnesen H (1992)
Introduction: the metabolic cardiovascular syndrome
J Cardiovasc Pharmacol, 20 Suppl 8, S1-4
DOI 10.1097/00005344-199200208-00001, PubMed 1283761

Eritsland J, Seljeflot I, Arnesen H, Smith P, Westvik AB (1992)
Effects of long-term treatment with warfarin on fibrinogen, FPA, TAT, and D-dimer in patients with coronary artery disease
Thromb Res, 66 (1), 55-60
DOI 10.1016/0049-3848(92)90155-4, PubMed 1412183

SLETNES KE, SMITH P, ABDELNOOR M, ARNESEN H, WISLOFF F (1992)
ANTIPHOSPHOLIPID ANTIBODIES AND RECURRENT THROMBOOCCLUSIVE EVENTS - REPLY
Lancet, 340 (8811), 117-118

Sletnes KE, Smith P, Abdelnoor M, Arnesen H, Wisløff F (1992)
Antiphospholipid antibodies after myocardial infarction and their relation to mortality, reinfarction, and non-haemorrhagic stroke
Lancet, 339 (8791), 451-3
DOI 10.1016/0140-6736(92)91057-f, PubMed 1346819

Smith P, Arnesen H, Abdelnoor M (1992)
Effects of long-term anticoagulant therapy in subgroups after acute myocardial infarction
Arch Intern Med, 152 (5), 993-7
DOI 10.1001/archinte.152.5.993, PubMed 1580727

Publications 1991

Arnesen H (1991)
[Resource-saving treatment of deep venous thrombosis with low molecular weight heparin--but is it good enough?]
Tidsskr Nor Laegeforen, 111 (27), 3266-7
PubMed 1659750

Arnesen H, Smith P (1991)
The predictability of bleeding by prothrombin times sensitive or insensitive to PIVKA during intensive oral anticoagulation
Thromb Res, 61 (3), 311-4
DOI 10.1016/0049-3848(91)90108-9, PubMed 1822957

Laerum E, Johnsen N, Smith P, Arnesen H (1991)
Positive psychological and life-style changes after myocardial infarction: a follow-up study after 2-4 years
Fam Pract, 8 (3), 229-33
DOI 10.1093/fampra/8.3.229, PubMed 1959722

Publications 1990

Andersen P, Smith P, Seljeflot I, Brataker S, Arnesen H (1990)
Effects of gemfibrozil on lipids and haemostasis after myocardial infarction
Thromb Haemost, 63 (2), 174-7
PubMed 2194314

SELJEFLOT I, ARNESEN H, SMITH P, ANDERSEN P (1990)
D-DIMER AGGLUTINATION-TEST IN THE EVALUATION OF FIBRINOLYTIC CAPACITY AFTER STIMULATION WITH DDAVP
Fibrinolysis, 4 (2), 125-126
DOI 10.1016/0268-9499(90)90008-8

Smith P, Arnesen H (1990)
Mortality in non-consenters in a post-myocardial infarction trial
J Intern Med, 228 (3), 253-6
DOI 10.1111/j.1365-2796.1990.tb00227.x, PubMed 2401875

Smith P, Arnesen H, Holme I (1990)
The effect of warfarin on mortality and reinfarction after myocardial infarction
N Engl J Med, 323 (3), 147-52
DOI 10.1056/NEJM199007193230302, PubMed 2194126

SMITH P, ARNESEN H, HOLME I (1990)
WARFARIN AFTER MYOCARDIAL-INFARCTION - REPLY
N. Engl. J. Med., 323 (26), 1840-1841

Smith P, Arnesen H, Opstad T, Kierulf P (1990)
Warfarin has no negative impact on fibrinolysis
Thromb Res, 58 (6), 653-6
DOI 10.1016/0049-3848(90)90311-y, PubMed 2201102

Publications 1989

Arnesen H (1989)
[Treatment of iliofemoral venous thrombosis--diagnosis of pulmonary embolism]
Tidsskr Nor Laegeforen, 109 (14), 1496
PubMed 2749634

Arnesen H (1989)
[Pharmacologic treatment of venous thromboembolism]
Tidsskr Nor Laegeforen, 109 (17-18), 1893-4
PubMed 2749673

Eritsland J, Arnesen H, Smith P, Seljeflot I, Dahl K (1989)
Effects of highly concentrated omega-3 polyunsaturated fatty acids and acetylsalicylic acid, alone and combined, on bleeding time and serum lipid profile
J Oslo City Hosp, 39 (8-9), 97-101
PubMed 2809856

Smith P, Arnesen H, Opstad T, Dahl KH, Eritsland J (1989)
Influence of highly concentrated n-3 fatty acids on serum lipids and hemostatic variables in survivors of myocardial infarction receiving either oral anticoagulants or matching placebo
Thromb Res, 53 (5), 467-74
DOI 10.1016/0049-3848(89)90201-6, PubMed 2660319

Publications 1988

Aursnes I, Smith P, Arnesen H, Akesson B (1988)
Correlation between plasma levels of selenium and antithrombin-III
Eur J Haematol, 40 (1), 7-11
DOI 10.1111/j.1600-0609.1988.tb00789.x, PubMed 3342861

Smith P, Arnesen H (1988)
Non-respondents in a post-myocardial infarction trial: characteristics and reasons for refusal
Acta Med Scand, 223 (6), 537-42
DOI 10.1111/j.0954-6820.1988.tb17692.x, PubMed 3291560

Smith P, Arnesen H, Dahl KH, Nilsen DW, Opstad T, Andersen P (1988)
A comparative study of venous occlusion and DDAVP stimulated fibrinolysis in normolipidemic subjects
Thromb Res, 52 (6), 655-60
DOI 10.1016/0049-3848(88)90138-7, PubMed 3148209

Smith P, Arnesen H, Laerum E, Johnsen N (1988)
[Might a myocardial infarction be a positive experience?]
Tidsskr Nor Laegeforen, 108 (27), 2243-5
PubMed 3206429

Publications 1987

Arnesen H, Engebretsen LF, Ugland OM, Seljeflot I, Kierulf P (1987)
Increased fibrinolytic activity after surgery induced by low dose heparin
Thromb Res, 45 (5), 553-9
DOI 10.1016/0049-3848(87)90318-5, PubMed 3109060

Dalaker K, Smith P, Arnesen H, Prydz H (1987)
Factor VII-phospholipid complex in male survivors of acute myocardial infarction
Acta Med Scand, 222 (2), 111-6
DOI 10.1111/j.0954-6820.1987.tb10646.x, PubMed 3673663

Publications 1986

Arnesen H, Smith P, Aspelund EB (1986)
Changes in fibrinolytic capacity and lipoprotein pattern during long-term treatment with warfarin
Thromb Res, 44 (2), 229-33
DOI 10.1016/0049-3848(86)90138-6, PubMed 2878510

Aursnes I, Dørum HP, Smith P, Arnesen H, Christiansen EN, Norum KR, Fischer S, Weber PC (1986)
Low and high risk coronary patients discriminated by blood platelet fatty acid composition
Scand J Clin Lab Invest, 46 (2), 115-20
DOI 10.3109/00365518609083646, PubMed 3715364

Smith P, Arnesen H (1986)
Warfarin and uric acid after myocardial infarction
Acta Med Scand, 220 (5), 407-10
DOI 10.1111/j.0954-6820.1986.tb02788.x, PubMed 3544688

Publications 1985

Augland E, Semb J, Eliassen GV, Berg JT, Arnesen H, Kjellemo LA, Eriksen E, Ness M (1985)
Materialsortering
Telemark ingeniørhøgskole, Porsgrunn
BIBSYS 922133689

Skjaeggestad O, Arnesen H (1985)
Primary ventricular fibrillation complicating acute myocardial infarction: incidence in subgroups
J Oslo City Hosp, 35 (9-10), 107-9
PubMed 4067712

Publications 1984

Arnesen H, Gaupås M, Gøystdal GO, Simensen FO, Aaman DR, Kåsa HR, Svendsen O (1984)
Småbåthavn
Telemark ingeniørhøgskole, Porsgrunn
BIBSYS 922132267

Publications 1983

ANDERSEN P, ARNESEN H, HJERMANN I (1983)
INCREASED FIBRINOLYTIC CAPACITY AFTER INTERVENTION ON DIET IN HEALTHY CORONARY HIGH-RISK MEN
SCAND J HAEMATOL, 30 39, 47-52

ARNESEN H, EYJOLFSSON O, HOL R (1983)
SUCCESSFUL TREATMENT WITH SELECTIVE INTRACORONARY STREPTOKINASE IN IMPENDING MYOCARDIAL-INFARCTION
SCAND J HAEMATOL, 30 39, 39-41

ARNESEN H, KIERULF P, GRAVEM K (1983)
THE PROLONGING EFFECT OF SOYBEAN TRYPSIN-INHIBITOR ON THE THROMBIN CLOTTING TIME
SCAND J HAEMATOL, 30 39, 81-85

ARNESEN H, SEMB G, HOL R, KARLSEN H (1983)
FIBRINOLYTIC CAPACITY AFTER VENOUS STASIS IN PATIENTS UNDERGOING AORTO-CORONARY BYPASS-SURGERY - RELATION TO SHUNT OCCLUSION
SCAND J HAEMATOL, 30 39, 43-46

Maeland A, Teieh AN, Arnesen H, Garborg I (1983)
Cardiobacterium hominis endocarditis
Eur J Clin Microbiol, 2 (3), 216-7
DOI 10.1007/BF02029519, PubMed 6884339

Skjaeggestad O, Arnesen H (1983)
[Incidence of ventricular fibrillation in acute myocardial infarction with and without the use of lidocaine]
Tidsskr Nor Laegeforen, 103 (7), 671-2
PubMed 6868044

Publications 1982

Arnesen H, Høiseth A, Ly B (1982)
Streptokinase of heparin in the treatment of deep vein thrombosis. Follow-up results of a prospective study
Acta Med Scand, 211 (1-2), 65-8
PubMed 7041523

Holter J, Arnesen H (1982)
[Unusual reason for death in a patient with known malignancy]
Tidsskr Nor Laegeforen, 102 (15), 852-3
PubMed 6984239

Publications 1981

Andersen P, Arnesen H, Hjermann I (1981)
Hyperlipoproteinaemia and reduced fibrinolytic activity in healthy coronary high-risk men
Acta Med Scand, 209 (3), 199-202
DOI 10.1111/j.0954-6820.1981.tb11576.x, PubMed 7223513

Arnesen H, Ly B (1981)
[Treatment of recent deep vein thrombosis. A supplement]
Tidsskr Nor Laegeforen, 101 (6), 404-5
PubMed 7209932

Publications 1980

Arnesen H, Skjaeggestad O, Wik B (1980)
Plasma free fatty acids and the incidence of arrhythmias in acute myocardial infarction during treatment with small doses of subcutaneous heparin or warfarin
Acta Med Scand, 207 (1-2), 21-5
DOI 10.1111/j.0954-6820.1980.tb09669.x, PubMed 7368968

Nordby E, Arnesen H, Andersen P, Godal HC (1980)
The euglobulin clot lysis time, a rapid and sensitive method for the assay of fibrinolytic activity after venous stasis
Scand J Haematol, 25 (5), 407-11
DOI 10.1111/j.1600-0609.1981.tb01421.x, PubMed 7221476

Wik B, Skjaeggestad O, Arnesen H (1980)
[The reliability of conventional arrhythmia detection in acute myocardial infarction and the significance of prophylactic lidocaine treatment]
Tidsskr Nor Laegeforen, 100 (27), 1595-7
PubMed 7444902

Publications 1979

Arnesen H, Bjerkedal I, Skjaeggestad O, Godal HC (1979)
Plasma free-fatty-acids and small doses of subcutaneous heparin in acute myocardial infarction
Thromb Res, 14 (4-5), 541-9
DOI 10.1016/0049-3848(79)90110-5, PubMed 483254

Arnesen H, Ly B (1979)
[Diagnosis and treatment of recent deep venous thrombosis and recent pulmonary embolism]
Tidsskr Nor Laegeforen, 99 (12), 591-3
PubMed 442035

Publications 1978

Arnesen H, Heilo A, Jakobsen E, Ly B, Skaga E (1978)
A prospective study of streptokinase and heparin in the treatment of deep vein thrombosis
Acta Med Scand, 203 (6), 457-63
DOI 10.1111/j.0954-6820.1978.tb14908.x, PubMed 352099

ARNESEN H, HEILO A, JAKOBSEN E, LY B, SKAGA E (1978)
PROSPECTIVE-STUDY OF STREPTOKINASE AND HEPARIN IN TREATMENT OF DEEP-VEIN THROMBOSIS
Acta Med. Scand., 203 (6), 457-463

Eika C, Arnesen H, Godal HC (1978)
The ethanol gelation test in pregnancy
Acta Obstet Gynecol Scand, 57 (5), 473-5
DOI 10.3109/00016347809156532, PubMed 726880

Ly B, Arnesen H, Eie H, Hol R (1978)
A controlled clinical trial of streptokinase and heparin in the treatment of major pulmonary embolism
Acta Med Scand, 203 (6), 465-70
DOI 10.1111/j.0954-6820.1978.tb14909.x, PubMed 352100

LY B, ARNESEN H, EIE H, HOL R (1978)
CONTROLLED CLINICAL-TRIAL OF STREPTOKINASE AND HEPARIN IN TREATMENT OF MAJOR PULMONARY-EMBOLISM
Acta Med. Scand., 203 (6), 465-470

Publications 1977

Arnesen H (1977)
Fibrinogen/fibrin degradation products (FDP/fdp). Characterization, anticoagulant activity, and influence on laboratory assays
J Oslo City Hosp, 27 (6), 69-80
PubMed 142131

ARNESEN H (1977)
FIBRINOGEN/FIBRIN DEGRADATION PRODUCTS (FDP/FDP) - CHARACTERIZATION, ANTICOAGULANT ACTIVITY, AND INFLUENCE ON LABORATORY ASSAYS
MEDIKON, 6 (4), 5-&

Arnesen H, Rygh M, Ly B, Jakobsen E (1977)
Streptokinase resistance in medical patients in Oslo
Scand J Haematol, 18 (4), 348-52
DOI 10.1111/j.1600-0609.1977.tb01207.x, PubMed 857296

Refsum N, Arnesen H, Gilhuus-Moe CC, Godal HC (1977)
The relationship between Normotest and Thrombotest in patients on oral anticoagulant therapy
Scand J Haematol, 18 (4), 333-6
DOI 10.1111/j.1600-0609.1977.tb01204.x, PubMed 854707

REFSUM N, ARNESEN H, GILHUUSMOE CC, GODAL HC (1977)
RELATIONSHIP BETWEEN NORMOTEST AND THROMBOTEST IN PATIENTS ON ORAL ANTICOAGULANT THERAPY
SCAND J HAEMATOL, 18 (4), 333-336

Publications 1976

Arnesen H, Akesson I, Strömme SB, Refsum HE (1976)
Fibrin/fibrinogen degradation products (FDP) in urine and serum after prolonged heavy exercise
Scand J Haematol, 16 (4), 279-84
DOI 10.1111/j.1600-0609.1976.tb01151.x, PubMed 935811

Publications 1975

Kierulf P, Arnesen H, Gravem K (1975)
Proceedings: The prolonging effect of soy bean trypsin inhibitor on the thrombin clotting time
Thromb Diath Haemorrh, 34 (1), 340
PubMed 1188775

Publications 1974

Arnesen H (1974)
The effect of products D and E on the thrombin induced conversion of fibrinogen to fibrin
Scand J Haematol, 12 (3), 165-72
DOI 10.1111/j.1600-0609.1974.tb00196.x, PubMed 4208835

Arnesen H (1974)
Characterization of fibrinogen and fibrin degradation products by isoelectric focusing in polyacrylamide gel
Thromb Res, 4 (6), 861-8
DOI 10.1016/0049-3848(74)90027-9, PubMed 4844064

ARNESEN H (1974)
EFFECT OF PRODUCT-D AND PRODUCT-E ON THROMBIN INDUCED CONVERSION OF FIBRINOGEN TO FIBRIN
SCAND J HAEMATOL, 12 (3), 165-172

Arnesen H (1974)
Studies on fibrinogen/fibrin degradation products: With special reference to characterization, anticoagulantactivity and influence on laboratory assays
Hematological Research Laboratory, Department IX, UllevålHospital, Oslo, 1 b. (flere pag.)
BIBSYS 991365100

Arnesen H, Ly B (1974)
FR-antigens in serum after coagulation at low pH
Thromb Res, 5 (1), 93-5
DOI 10.1016/0049-3848(74)90112-1, PubMed 4428472

Ly B, Kierulf P, Arnesen H (1974)
Molecular aspects of the clottable proteins of human plasma during fibrinogenolysis
Thromb Res, 5 (3), 301-14
DOI 10.1016/0049-3848(74)90169-8, PubMed 4216116

Publications 1973

Arnesen H (1973)
Studies on the thrombin clotting time. II. The influence of fibrin degradation products
Scand J Haematol, 10 (4), 291-7
PubMed 4764611

Arnesen H (1973)
[Present situation of fibrinolytic therapy]
Tidsskr Nor Laegeforen, 93 (35), 2579-81
PubMed 4772810

Arnesen H (1973)
Quantitation of plasma fibrinogen in the presence of fibrinogen degradation products
Scand J Haematol, 11 (3), 204-9
DOI 10.1111/j.1600-0609.1973.tb00118.x, PubMed 4797270

Arnesen H (1973)
Førstehjelp: alpint
Norges skiforbund, oslo, 8 s.
BIBSYS 010440747

Arnesen H, Godal HC (1973)
Studies on the thrombin clotting time. I. The influence of fibrinogen degradation products
Scand J Haematol, 10 (3), 232-40
DOI 10.1111/j.1600-0609.1973.tb00065.x, PubMed 4797626

Arnesen H, Kierulf P, Godal HC (1973)
The influence of fibrinogen degradation products on the reptilase-time of plasma
Scand J Haematol, 11 (5), 360-6
DOI 10.1111/j.1600-0609.1973.tb00144.x, PubMed 4798341

ARNESEN H, KIERULF P, GODAL HC (1973)
INFLUENCE OF FIBRINOGEN DEGRADATION PRODUCTS ON REPTILASE TIME OF PLASMA
SCAND J HAEMATOL, 11 (5), 360-366

LY B, ARNESEN H (1973)
INFLUENCE OF PH ON INCORPORATION OF FIBRINOGEN DEGRADATION PRODUCTS INTO FIBRIN CLOTS AS STUDIED BY TRACER TECHNIQUE
Haemostasis, 2 (5), 198-208

Myśliwiec M, Arnesen H, Godal HC (1973)
The effect of fibrinogen degradation products on plasmin activity
Thromb Diath Haemorrh, 29 (3), 592-7
PubMed 4271546

MYSLIWIEC M, ARNESEN H, GODAL HC (1973)
EFFECT OF FIBRINOGEN DEGRADATION PRODUCTS ON PLASMIN ACTIVITY
THROMB DIATH HAEMOST, 29 (3), 592-597

Publications 1972

Arnesen H, Fagerhol MK (1972)
2 -Macroglobulin, 1 -antitrypsin, and antithrombin III in plasma and serum during fibrinolytic therapy with urokinase
Scand J Clin Lab Invest, 29 (3), 259-63
DOI 10.3109/00365517209080240, PubMed 4114014

Arnesen H, Godal HC (1972)
[Simple routine method for fibrinogen determination]
Tidsskr Nor Laegeforen, 92 (24), 1526-7
PubMed 5076540

Publications 1971

Arnesen H (1971)
[Fibrinolytic treatment of pulmonary embolism]
Tidsskr Nor Laegeforen, 91 (29), 2110-1
PubMed 5130883

Arnesen H (1971)
[Fibrinolytic therapy of venous thrombosis]
Tidsskr Nor Laegeforen, 91 (29), 2130-4
PubMed 5130893

Arnesen H (1971)
Fibrinogen degradation products and fibrinogen to fibrin conversion
Scand J Haematol Suppl, 13, 245-52
DOI 10.1111/j.1600-0609.1971.tb02015.x, PubMed 5290685

Arnesen H (1971)
Isoelectric focusing of fibrinogen degradation products
Scand J Haematol Suppl, 13, 43-7
DOI 10.1111/j.1600-0609.1971.tb01983.x, PubMed 5290702

Publications 1970

Arnesen H, Eika C, Kierulf P, Monn E, Vogt H (1970)
Disseminated intravascular coagulation (DIC) in the newborn
Acta Paediatr Scand Suppl, 206, Suppl 206:29+
DOI 10.1111/j.1651-2227.1970.tb14553.x, PubMed 5276972

Arnesen H, Ly B (1970)
[Case of lung embolism treated with streptokinase]
Tidsskr Nor Laegeforen, 90 (14), 1470-2
PubMed 5452272